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1   Introduction 
 
1.1   Historical Background 
Although at least some of the closely related neurodegenerative conditions known as 
transmissible spongiform encephalopathies (TSEs) or prion diseases have been recognised for 
many years, only in the last two decades decisive steps have been made in the characterisation 
of their underlying causes. These rapidly progressing fatal syndromes can affect both humans 
and animals and present scientists and public health with distinctive phenomena and 
challenges. This is because of the unique biology of the transmissible agent and because of 
the fear that the epidemic of the bovine prion disease BSE, with more the 180,000 cases in the 
U.K. and numerous confirmed cases in other European countries, could represent a threat to 
public health through dietary exposure. In 1996 a direct link between BSE and a novel form 
of the human Creutzfeldt-Jakob disease was argued for (Will et al., 1996; Collinge et al., 
1996b;Will, 1998).  
The nature of the agent in these disorders has been a matter of debate for many years. The 
naturally occurring scrapie disease affecting sheep and goat  present in many countries world 
wide was first described as early as 1732. In 1936 inoculation between sheep (and goat) 
showed that scrapie could be transmitted after prolonged incubation. Some kind of virus was 
therefore assumed to be the causative agent and in 1954 Sigurdson referred to it as a “slow 
virus”, due to incubation times as long as 20 years. Five years later Hadlow drew attention to 
the similarities between scrapie and kuru, a disease of New Guinea highlanders, at a 
neuropathological and clinical level. Intracerebral inoculation of chimpanzees with brain 
homogenates a few years later established the transmissibility of kuru (Gajdusek et al., 1966). 
Similarities in the pathology of the central nervous system (CNS) also showed a link between 
these and another human disease, the Creutzfeldt-Jakob disease (CJD), a rare 
neurodegenerative condition, the etiology of which had been unknown for decades (it had first 
been described in 1920). In 1968 also the transmission of CJD to chimpanzees after 
intracerebral inoculation was reported (Gibbs, Jr. et al., 1968).  
In spite of the initial assumption for the causative agent of  TSEs, no virus or immunological 
response was found. In 1966 Tikvah Alper and colleagues found that the scrapie agent was 
resistant to UV- inactivation and ionising radiation, treatments that would inactivate nucleic 
acids, whereas infectivity could be reduced by procedures that hydrolyse or modify proteins 
(urea or treatment with NaOH) (Alper et al., 1966). These findings led to the conclusion of an 
agent devoid of nucleic acid and in 1967 Griffith suggested that the transmissible agent might 
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be a protein (Griffith, 1967). In 1982 the Prusiner group isolated a protease resistant 
glycoprotein which was the major constituent of the infective fraction in affected brain 
homogenate and sometimes formed amyloid deposits in form of filamentous structures called 
scrapie-associated-fibrils (SAFs) or prion rods (Lehmann and Harris, 1996; Hilmert and 
Diringer, 1984; Prusiner et al., 1981;Prusiner, 1982). Prusiner therefore proposed the 
definition “prion” as a proteinaceous infectious particle that lacks nucleic acid. In enriched 
fractions of Syrian hamster (Sha) brains the isolated proteinase-K (PK)-resistent protein was 
of 27-30 kDa (PrP27-30) and was derived from a larger molecule of 33 to 35 kDa, designated 
PrPSc (denoting the infectious scrapie character of this protein). Determination of the NH2-
terminal sequence of the PrPSc by Edman degradation finally made molecular cloning studies 
of the PrP gene (prnp) possible (Prusiner et al., 1984). The findings that PrP mRNAs were 
identical in uninfected and scrapie infected tissues, and that antibodies raised in mice against 
infected hamster PrP also reacted with uninfected tissues led to isolation of  a non- infectious 
cellular isoform of the prion protein denoted PrPc (Oesch et al., 1985; Meyer et al., 1986). 
The two isoforms of the prion protein shared the same amino acid sequence, but differed 
significantly in their biochemical properties (Prusiner, 1991). 
 
Characteristics  PrPc PrPSc 
Infectivity 
Secondary structure 
Half life time 
Proteinase-K (PK) digestion 
Ultracentrifugation in detergents  
No 
Mainly α-helical  
2-6 hours 
Sensitive 
Soluble  
Yes 
Mainly β-sheet 
16-24 hours and longer 
Partially resistant 
Insoluble  
 
Table 1:  Features of the cellular and pathogen isoforms of the prion protein: a comparison  
 
1.2   Animal prion diseases 
Both human and animal prion diseases share common histopathological features. Examination 
of the CNS typically shows spongiform degeneration affecting different parts of the grey 
matter, neuronal loss and astrocytic  proliferation which can be accompanied by amyloid 
plaques. The degree of spongiform vacuolation is quite variable and the extent of astrocytic 
proliferation correlates with the degree of neuronal loss. 
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Disease Host Cause 
Scrapie 
 
 
 
TME (transmissible mink encephalopathy) 
 
 
CWD (chronic wasting disease) 
 
 
BSE (bovine spongiform encephalopathy) 
 
 
FSE (feline spongiform encephalopathy) 
Sheep/ Goat 
 
 
 
Mink 
 
 
Deer, elk 
 
 
Cattle 
 
 
Cats 
 
Vertical and horizontal infection 
in genetically susceptible sheep; 
oral transmission; sporadic 
 
Infection with contaminated 
meat from sheep and cattle 
 
Unclear, possibly similar to 
scrapie 
 
Infection with prion- 
contaminated food; sporadic (?) 
 
Infection with contaminated 
bovine tissue and food 
 
Table 2: The animal prion diseases 
 
Besides scrapie, more recently recognised animal diseases like transmissible mink 
encephalopathy  (TME) (Marsh and Hadlow, 1992) and chronic wasting disease (CWD) in 
deer and elk (Shyng et al., 1995b) were described in captive animals, mainly in the USA 
together with the bovine spongiform encephalopathy or BSE in the United Kingdom (Wells et 
al., 1987). Chronic wasting disease seems to be a common condition in wild deer and elk in 
areas of Colorado, Wyoming and Montana (Spraker et al., 1997). The routes of transmission 
remain unclear. Transmissible mink encephalopathy has occurred as infrequent epidemics 
along captive mink in UK and USA, long before BSE, and in Russia. The disease is probably 
caused by exposure to sheep and cattle prion via contaminated food.  
BSE was first described in UK cattle in 1986 and evolved rapidly to an epidemic. The cows 
initially became apprehensive and uncoordinated, their mental status deteriorated and they 
became hard to handle. In some cases they progressed to frenzy, which led to the name “mad 
cow disease”. Contaminated meat and bone meal prepared from carcasses of sheep and cattle 
as a high protein nutritional supplement for dairy cows was recognised to be its probable 
cause. One possibility for the raise of BSE is that changes in the rendering processes 
introduced in the United Kingdom in the late 1970s  (e.g. the use of hydrocarbon organic 
solvents had been stopped) allowed scrapie  prion from sheep to survive  and to be passed to 
cattle. An alternative hypothesis is that epidemic BSE resulted from recycling of rare sporadic 
BSE into cattle by oral inoculation with food. More than 180,000 clinical BSE cases have 
been confirmed in cattle in the UK although the total number of infected animals has been 
estimated at around one million (Anderson et al., 1996). The ban of food derived from animal 
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carcasses in 1988 to sheep and cattle has now led to a drastic reduction of the epidemic. In the 
90s, a number of BSE cases has been reported in other European countries like Switzerland, 
Ireland and Portugal. Recently diagnosed BSE cases in German cattle due to import of food 
from the UK has led to compulsory testing for all slaughterhouse cows older than 24 months 
in Germany, following the EU-regulations introduced in 2001. So far more than 100 animal 
were tested positive. Immunoassays for PrPSc in the brainstem of cattle might provide a 
reasonable approach to establishing the incidence of subclinical BSE. Newly recognised prion 
diseases can also affect domestic and wild cats (Lehmann and Harris, 1996) and a number of 
zoo animals (Jeffrey and Wells, 1988; Kirkwood et al., 1990). These new diseases have 
developed at the same time or following the emergence of BSE, and several of these have 
been seen to be caused by the BSE prion strain (Bruce et al., 1994; Collinge et al., 1996b). 
Nevertheless, many domestic animals show resistance to infection with prion: no case of 
TSEs could be detected in dogs or birds, and pigs could not be orally infected, so far. 
 
1.3   Human Prion Diseases 
Depending on their etiology, human prion conditions can be divided into three categories: 
sporadic, acquired and inherited. Accidental exposure to human prions through medical or 
surgical procedures as for iatrogenic Creutzfeldt-Jakob disease (iCJD) or participation in 
cannibalistic ceremonies as in the case of kuru are the origin of acquired prion diseases in 
humans. The appearance in the UK in 1995 of a novel human prion disease, variant CJD 
(vCJD) probably derived by dietary exposure to cattle BSE has extended the list of acquired 
TSEs. Around 10-15 % of all human prion diseases are inherited and have been associated 
with autosomal dominant mutations in the prion protein gene. Over 20 distinct point 
mutations have been characterised (Collinge, 1997) and can be diagnosed by prnp analysis. 
This has allowed recognition of a range of atypical dementias and of the fatal familial 
insomnia (Collinge et al., 1992; Gambetti et al., 1995). No pathogenic PrP mutations are 
present in sporadic prion diseases.  
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Disease Mechanism of infection 
Kuru 
CJD: 
   Familial 
   Sporadic 
   Iatrogenic 
 
   Variant CJD 
 
GSS (Gerstmann-Sträussler-
Scheinker disease) 
 
FFI (fatal familial insomnia) 
Acquired through cannibalistic rituals 
 
Inherited (mutation in the PrP gene) 
Spontaneous conversion of PrPc into PrPSc  (?) 
Acquired from contaminated instruments, dura mater grafts or 
growth hormone 
Acquired (infection by bovine prions) 
 
Inherited (mutation in the PrP gene) 
 
 
Inherited (mutation in the PrP gene) 
 
 
Table 3: The human prion diseases 
 
Classical (sporadic) CJD is a rapidly progressive multifocal dementia occurring in all 
countries with an incidence of one per million inhabitants. Usually,  the age of onset of the 
disease is 45 to 75 with death occurring 3-6 months after onset of the symptoms. Insomnia, 
fatigue, depression, loss of weight, headache and general pain sensations are characteristic 
symptoms, neurological features include ataxia, pyramidal signs and cortical blindness. 
Kuru provides the largest experience of acquired human prion disease with the earliest cases 
dating back to the beginning of the 20th century. This disease affected a defined population 
living in the Eastern Highlands of Papua New Guinea (the Fore linguistic group and their 
neighbours) reaching epidemic proportions. It affected predominantly women and children of 
both sexes and was the most common cause of death among women in affected villages. Kuru 
was transmitted during cannibalistic rituals when deceased members of the community were 
consumed by their close relatives. Women and children predominantly participated in these 
feasts and ate brain and internal organs, which might explain age and sex of incidence. The 
epidemic probably originated from a sporadic case of CJD which occurred in this population 
and was re-introduced when the individual was consumed. The precise estimate of the 
incubation period of the disease is complicated by the multiple exposure that individual kuru 
patients might have had. Infrequent cases of kuru recorded in children as young as 4.5 years 
indicate incubation times of this order or less. However, although dietary exposure was the 
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principal route of transmission, inoculation with brain or other tissue via cuts or sores was 
also likely (Prusiner et al., 1982). On the other hand, occasional cases of kuru still occur in 
some individuals exposed during the last ceremonies held in their villages in the 1950s and 
are consistent with incubation periods longer than 40 years. After cession of cannibalism in 
the late 1950s the number of cases decreased significantly and none of the individuals born 
after the ban showed symptoms. The central clinical feature of the disease is progressive 
cerebellar ataxia and, in contrast to CJD, dementia is often absent. The mean clinical duration 
of illness is 12 months. 
Although prion diseases can be transmitted experimentally to animals by inoculation, they 
cannot be transmitted to humans via family or sexual contact. Besides cannibalism, the only 
documented human case-to-case spread occurred by the use of inadequately sterilised 
intracerebral electrodes, dura mater and corneal grafting and from the use of human cadaver 
growth hormone or gonadotropin. Of note, cases arising from intracerebral or optic 
inoculation clinically manifest  as classical CJD, with rapidly progressive dementia, whereas 
peripheral inoculation often results in kuru-reminding ataxia. Even incubation period after 
intracerebral inoculation is shorter (19-46 months for dura mater grafts) compared with 
peripheral cases (mean estimation 15 years).  
The pathogenic mutations identified in the prion protein gene are all autosomal dominant and 
can be divided into two groups: point mutations resulting in amino acid substitution (or 
truncation) in the PrP molecule or insertions encoding additional copies of two or more of the 
five octapeptide repeats usually present in the normal PrP. These mutations are believed to 
destabilise the prion protein, which then undergoes spontaneous conformational change 
(Owen et al., 1989; Ghetti et al., 1996). Besides familial cases of CJD (10  % of all CJD 
cases), the Gerstmann-Sträussler-Scheinker disease (GSS) is another autosomal dominant 
disorder presenting with chronic cerebellar ataxia and dementia occurring later in a more 
prolonged clinical course than in CJD. Histologically, amyloid PrP-plaques represent a 
hallmark of the disease. The mean duration is approximately 5 years, with onset in the third or 
fourth decade. First associated with the P102L prnp mutation (Hsiao et al., 1989), GSS is now 
linked to seven different PrP mutations and forms part of the phenotypic spectrum of inherited 
prion diseases. 
The phenotypes in families with inherited prion diseases can show remarkable variability 
ranging from classical CJD to GSS as well as to other cases that do not conform to either of 
those syndromes. The classical histological features can be seen in variable combinations or 
lack completely. The latest discovered inherited form of prion disorder is the fatal familial 
 6
 Introduction 
__________________________________________________________________________________________ 
insomnia (FFI), characterised by mutation of codon 178 of prnp from Asp to Asn (Parchi et 
al., 1998; Goldfarb et al., 1992) associated with the PrP-allele methionine at codon 129. 
Affected individuals are usually over 50 years of age and usually die one year after onset of 
symptoms. A possible rare sporadic origin of this disease has been recently suggested 
(Kretzschmar, unpublished data). 
 
Figure 1. Mutations causing inherited prion diseases and polymorphisms in humans.  
 
Above the line of the human sequence are mutations that cause prion disease. Below the lines are 
polymorphisms, some but not all of which are known to influence the susceptibility as well as the 
phenotype of disease. (From Collinge, 2001) 
   
1.3.1   Variant CJD 
Concern over the possibility of transmission of BSE to humans led to re-establishment in 
1990 of  a comprehensive system of national surveillance for CJD in the UK directed toward 
detection of any rise in the incidence of human prion disease. In fact, in 1994 (Will et al., 
1996; Collinge and Rossor, 1996) several cases of CJD in teenagers and young adults were 
observed and reported. Up to November 2002 a total of 117 probable cases have been referred 
in the UK with 6 cases in France, one in the Republic of Ireland and one in Italy. The disease, 
initially named new variant CJD, now simply variant CJD (vCJD), presented a clinical picture 
that contrasted with all forms of classical CJD.  The most striking clinical difference  between 
classic and variant CJD is the downward shift in the average age of affected individuals for 
vCJD with a range of 16 to 53 years. The rate of progression is marginally slower than that of 
cCJD with a mean duration of 14 months. In the clinical presentation, behavioural and 
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psychiatric disturbances predominate (Zeidler et al., 1997), (Hill et al., 1999) and the most 
dominant symptoms are depression and behavioural changes. Cerebellar syndromes and 
ataxia also develop, dementia usually appears later in the clinical course. The most 
remarkable neuropathological characteristic is the accumulation of PrP amyloid plaques in 
cerebral and cerebellar cortex, consisting of kuru-like spongiform vacuoles (“florid plaques”) 
(Will et al., 1996). Another unique characteristic is that PrPSc can be detected in tonsils and 
other lymphoreticular  tissues in patients affected with vCJD, which is not the case in other 
forms of human prion diseases. All patients to date are homozygous for methionine at prnp 
codon 129 (Collinge et al., 1996b).  
A number of data today indicate a direct link between BSE and vCJD initially supported by 
the restricted  geographical occurrence and chronology of vCJD. Molecular strain typing 
showed that the glycoform ratios of PK digested PrPSc in vCJD were identical with those seen 
in BSE passaged in a number of mammalian species (Collinge et al., 1996a). In 1997 inbred 
mice that had been inoculated with homogenates of brains from three vCJD patients were 
reported to show the same BSE strain characteristic (incubation period and lesion profile) 
(Bruce et al., 1997; Hill et al., 1997). Macaque monkeys also developed neurologic disease 
several years after inoculation with bovine prions exhibiting plaques similar to those found in 
vCJD (Lasmezas et al., 1996). In 1989 the British banned the use of specified types of bovine 
offal in food for human consumption. Until then homogenates of pooled bovine brains had 
been used as binders for foods such as hamburgers and sausages. Humans could therefore 
have ingested food with high titers of infected agent. If the cases of vCJD were contracted 
before this ban, the minimal incubation period would probably be around 10 years. 
So far it remains difficult to usefully estimate the total magnitude of a possible vCJD 
epidemic by extrapolation from the current. Statistics and reports of the number of individuals 
who will develop vCJD in the next years range from hundreds to many thousands (Donnelly 
et al., 2002; Ghani et al., 2002). 
 
1.4   Therapeutic and prophylactic approaches 
Numerous approaches have been undertaken  for experimental prophylaxis or therapy of prion 
diseases. Since the brain suffers severe damage during the course of TSEs, including 
widespread neuronal loss, even in the early clinical phase of the disease, it is difficult to think 
that this damage can be reversed by pharmacological treatment. A different strategy is the use 
of substances which might prolong the incubation time and decelerate the pace of the disease 
by inhibiting the accumulation of PrPSc or the conversion of PrPc into its pathogenic isoform. 
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Among these, Congo Red, polyene antibiotics, anthracycline derivatives, sulphated 
polyanions, porphyrins, branched polyamines, Suramin and β-sheet breaker peptides have 
been seen to exert an effect in animal models or in cell culture systems. The effects exerted by 
some of these agents result primarily from their ability to interfere with trafficking of PrPc 
either by stimulating its endocytosis (as in the case of Pentosan and Dextran Sulphate) or by 
re-routing the protein to acidic compartments (as for Suramin), so that the location of 
conversion is by-passed. Strategies for intervention in case of post-exposure prophylaxis also 
deal with the fact that, in some TSEs, follicular dendritic cells (FDC) and secondary lymphoid 
organs are essential for prion replication  (Hilton et al., 1998; Hill et al., 1999, Brown et al., 
1999; Beekes and Mc Bride, 2000, Mabbot et al., 2000, Bruce et al., 2001). The molecules 
involved in this replication and accumulation step can therefore represent attractive targets for 
post-exposure prophylaxis. Recent data on the role of the immune system in prion diseases 
(Klein et al., 1997; Klein et al., 2001; Mabbott and Bruce, 2001) and immunisation studies in 
mouse models for Alzheimer disease (Ingram, 2001) have suggested a possible vaccination 
strategy against prion infection. Anti-PrP monoclonal antibodies and recombinant Fab 
fragments have shown pronounced effect in suppressing prion replication in cultured prion-
infected cells. A humoral immune response against PrPc and PrPSc is difficult to induce due to 
the fact that PrPc is a ubiquitous endogenous protein and an autotolerance within mammalian 
species represents a major obstacle in a vaccination approach. This is not the case when prnp 
is ablated or when PrP of a different species is used as an immunogen (Prusiner et al., 1993; 
Williamson et al., 1996). Of note, no innate or antigen-induced immune response is observed 
in natural prion infections (Prusiner, 1998; Weissmann et al., 2001). In a recent work, 
transgene expression of the heavy chain of an anti PrP antibody in mice prevented scrapie 
pathogenesis after intraperitoneal inoculation with prions (Heppner et al., 2001). 
 
1.5   PrP gene structure  
The PrP gene is mapped to the short arm of human chromosome 20 and to the homologous 
region of mouse chromosome 2 (Robakis et al., 1986; Sparkes et al., 1986) and is highly 
conserved in evolution (Schatzl et al., 1995; Wopfner et al., 1999). The entire open reading 
frame (ORF) of all known PrP genes resides within a single exon (Hsiao et al., 1989; Gabriel 
et al., 1992; Schatzl et al., 1995). The mouse, sheep, cattle and rat PrP genes contain three 
exons with the entire ORF in exon 3 (Westaway et al., 1991; Saeki et al., 1996) which is 
analogous to exon 2 of the Syrian hamster (Sha) gene (Basler et al., 1986). Exon 1 of the 
ShaPrP includes a portion of the 5´ untranslated leader sequence, while exon 2 includes the 
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ORF and the 3´ untranslated region. The promoters of PrPs are devoid of a TATA box and 
contain multiple copies of G+C rich repeats for binding of the transcription factors Sp-1 and 
AP-1 (McKnight and Tjian, 1986). Since the entire protein coding region is contained within 
a single exon, there is no possibility for the two protein isoforms to be the product of 
alternatively spliced mRNA (Basler et al., 1986). 
 
1.6   The function of the prion protein  
PrP has been identified in mammals, birds (Harris et al., 1993), marsupials (Windl et al., 
1995) and amphibians (Strumbo et al., 2001). The highest PrPc concentration is found in 
neurons (Kretzschmar et al., 1986), the protein follows an axonal pathway (Borchelt et al., 
1994) and localises mainly at synaptic (Fournier et al., 1995) or presynaptic ends (Herms et 
al., 1999). Although the highest levels of expression are seen in the central nervous system, 
the protein is found in most tissues and is widely expressed in cells of the immune system 
(Dodelet and Cashman, 1998). Its precise function has so far remained obscure. Gene knock-
out of prnp in mice did not lead to pronounced phenotype (Bueler et al., 1992) although these 
mice were completely resistant to prion following inoculation and  did not replicate prions 
(Bueler et al., 1993). These knock-out animals were eventually shown to have abnormalities 
in the synaptic physiology (Collinge et al., 1994) and in circadian rhythms and sleep (Tobler 
et al., 1996). A second physiological phenotype for prnp knock-out mice was reported later, 
with a reduction of slow after-hyperpolarisations evoked by trains of action potentials 
(Colling et al., 1996). This effect could be explained by abnormal homeostasis of intracellular 
Ca+. One of the possible roles for PrPc might be that of a receptor for an extracellular ligand. 
The transmembrane laminin receptor precursor (LRP) was shown to bind to PrP on the 
surface of mammalian cells (Rieger et al., 1997; Gauczynski et al., 2001). Other identified 
intracellular interactors include HSP 60 (Edenhofer et al., 1996) and Bcl-2 (Kurschner and 
Morgan, 1996). Several data argue for a role of the prion protein in copper metabolism related 
to the finding, that the prion protein can bind copper ions (Brown et al., 1998; Pauly and 
Harris, 1998). It has been shown that the Cu2+ content in membrane preparation of PrP0/0 mice 
was reduced to 50 % of that of wild type mice (Brown et al., 1997b). These mice also show a 
higher sensitivity to copper toxicity in oxidative stress conditions (Brown et al., 1996; Pauly 
and Harris, 1998). A superoxide-dismutase activity or a role as a carrier protein for uptake and 
delivery of metal ions from the extracellular space into the cell have been discussed, (Brown 
et al., 1997a; Brown et al., 1999). Synthetic peptides corresponding to the histidine rich 
octapeptide repeats (residues 50-90), and to peptides encompassing residues 60-91 or 23-98 
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have been seen to bind copper (II) ions (Pauly and Harris, 1998; Hornshaw et al., 1995). 
Studies done with CD spectroscopy and NMR (Viles et al., 1999) or mass spectrometry 
(Whittal et al., 2000) confirmed this affinity proposing a pH dependence of binding and 
stoichiometry. Recently, a second site around histidines 96 and 111 of human PrP, a region of 
the molecule known to be crucial for prion propagation, has been described (Jackson et al., 
2001). 
 
1.7   The structural properties of the prion protein 
Numerous data support the concept that prions consist principally or entirely of an abnormal 
isoform of the cellular prion protein (PrPc), named PrPSc. The pathogenic protein acts as a 
template  promoting a conformational change of PrPc (Borchelt et al., 1990; Caughey and 
Raymond, 1991) in a postranslational contact.  
Following translation of the PrP-mRNA the mouse PrP is composed of 254 amino acids, the 
first 22 of which function as signal peptide for translation of the polypeptide chain into the 
endoplasmic reticulum (Oesch et al., 1985). After cleavage of another C-terminal peptide, the 
molecule acquires a glycosyl-phosphatidyl-inositol (GPI) anchor. The polypeptide chain 
undergoes further posttranslational modifications resulting in the possible addition of 2 N-
linked carbohydrate chains  at Asn181 and Asn197. A single disulphide bond between 
Cys179 and Cys214 stabilises the conformation of the protein. After cleavage of the N- and 
C-terminal signal peptides, the mature human protein comprises 209 amino acids.  
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Figure 2. Primary structure of human PrPc before and after maturation.  
 
(A) The N- and C terminal signal peptides are cleaved from the translation product and a glycosyl 
phophatidyl inositol (GPI) anchor is attached to the C-terminal end of the protein. The molecule can 
be N-glycosylated twice (CHO), and disulfide bond (S-S) is built. The final product consists of 209 
amino acids. (B) Structure of PrPc as it is attached to the outer leaflet of the plasma membrane via its 
GPI anchor. Carbohydrate molecules are shown in yellow  (from Peretz, 2001) 
 
Properly folded PrPc transits through the Golgi compartment and the secretory pathway and is 
attached to the outer leaflet of the cellular plasma membrane by the GPI-anchor (Borchelt et 
al., 1990; Taraboulos et al., 1990b;Caughey, 1991). From here internalisation seems to occur 
through caveolae-like domains (CLD) or in rafts, membranous domains or invaginations of 
the plasma membrane rich in cholesterol and glycosphingolipids (Taraboulos et al., 1995). 
Cell surface localisation of PrPc is thought to be essential for subsequent conversion into PrPSc 
(Borchelt et al., 1990; Taraboulos et al., 1990b;Caughey, 1991) since conversion into PrPSc 
has been reported to occur close to the plasma membrane along the endocytic pathway, 
probably in CLD or in rafts (Taraboulos et al., 1995). Here also the first steps in PrP 
degradation occur (Vey et al., 1996; Kaneko et al., 1997a). After internalisation, PrP is 
transported to endosomes, from where it can either recycle to the cell surface (Vey et al., 
1996) or reach acidic compartments for final degradation. Late endosomes or lysosomes 
might be another compartment for prion propagation, as the low pH might facilitate un- and 
re-folding (Taraboulos et al., 1992; Arnold et al., 1995). After conversion, PrPSc accumulates 
in lysosomes and its degradation occurs at a very low rate. 
 
  
Endosomes
Endoplasmic
reticulum 
 
 
 
Raft 
 
 
 
 
 
 
 
 12
 Introduction 
__________________________________________________________________________________________ 
 
 
 
 
 
Figure 3. Cellular trafficking of PrPc 
 
After being transported along the secretory pathway and reaching the cell surface, where it is localised 
in cholesterol rich rafts. PrPc is internalised  into endosomes and reaches lysosomes for degradation or 
is recycled back to the plasma membrane. (Modified from Lehmann, 1997) 
 
1.7.1   The conformation of PrPc and PrPSc 
For many years, the idea that the amino acid sequence specifies one biologically active 
conformation of a protein had been accepted (Anfinsen, 1973). Nevertheless when purified 
PrPSc and PrPc were isolated, the secondary structure of the two PrP isoforms sharing the 
same amino acid sequence were compared by optical spectroscopy and were found to be 
different (Pan et al., 1993). The structure of the prion protein seemed to adopt two different 
conformations. Fourier-transform infrared spectroscopy (FTIR), mass spectrometry (Stahl et 
al., 1993) and circular dichroism (CD) studies showed that PrPc contains about 42 % α-helix 
and 3 % β-sheets, whereas PrPSc is composed of about 30 % α-helix and 45 % β-sheet (Pan et 
al., 1993; Gasset et al., 1993; Pergami et al., 1996). Since it has been impossible so far to 
produce crystals of PrP, the three dimensional structure of PrPc has not been measured by 
crystallographic analysis. The structure of a fragment of purified and refolded mouse PrP 
encompassing aa 121-231 expressed in E. coli was nevertheless analysed by nuclear magnetic 
resonance (NMR) (Riek et al., 1996) which confirmed a short two stranded antiparallel β-
sheet and 3 of the four α-helices predicted earlier (aa 144-154, 175-193, 200-219) by 
computer modelling (Cohen et al., 1994). The tertiary  structure of the full length protein (aa 
23-231) was subsequently characterised (Riek et al., 1997), a defined structure of the N-
terminal part of the protein (aa 23-120) could not be identified. Since then, NMR 
measurements on recombinant hamster (James et al., 1997) human and bovine PrP (Hosszu et 
al., 1999) show that they have essentially the same conformation. The  N-terminal part of 
most known PrPs contains a region formed by the repetition of five consecutive, eight residue 
long peptides, rich in glycine, proline and histidine (octarepeats). In mouse, they comprise 
amino acid 50 to 90. Binding of this region in vivo to metal ions and other possible ligands 
might nevertheless lead to a defined globular conformation. New data indicate the possible 
presence of a poly-L-proline type II –helix structure in the in vivo conformation of the prion 
polypeptide chain (Gill et al., 2000). 
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A        B 
    
                                                                                                                
Figure 4. Proposed NMR structure of PrPc and PrPSc 
  
(A) Syrian hamster recombinant PrPc(113–231) is viewed from the interface where PrPSc is thought to 
bind to PrPc. Residues 90-112 are not shown. Three main α-helices A (residues 144–157), B (172–
193), and C (200–227) can be seen. (B) Plausible model for the tertiary structure of HuPrPSc with 
predominant β-strands structure (From Prusiner, 1998) 
 
 
1.7.2   Mechanisms of prion conversion 
The protein-only hypothesis for the propagation of prions proceeds from the assumption that  
the PrPc of the host is converted into PrPSc by a direct interaction with exogenous scrapie 
protein. The major conformational change that causes PrPc to become pathogenic is thought to 
involve refolding of the region between residues 90 and 112, which would lead to conversion 
of the two short β-sheet structures and the first α-helix into a large β-sheet formation. 
However, the remaining C-terminal structures including the other two α-helices and the 
disulphide bonds need to be preserved for PrPSc to be infectious (Prusiner, 1998; Hornemann 
et al., 1997; Wille et al., 2002). By these means, the predominantly β-sheet conformation of 
the pathogenic protein is transmitted to the native α-helical structure of the cellular isoform. 
Two current models provide possible explanations for this mechanism. 
According to the heterodimer hypothesis proposed by Prusiner (Prusiner et al., 1990; Cohen 
et al., 1994), PrPc is partially unfolded into a transitional state designated PrP* and then 
refolded under the influence of PrPSc, which results in the formation of a homodimer 
complex, possibly along with a hypothetical molecular chaperone. The newly generated PrPSc 
can again induce conversion of PrPc in an autocatalytic process. The energy barrier for this 
conversion is probably very high (Cohen et al., 1994) and spontaneous forms of the disease 
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only appear at an advanced age. Specific mutations promoting β-sheet conformation can 
therefore explain hereditary form of disease by lowering the energy barrier. 
The nucleation dependent polymerisation model was first defined by the group around 
Gajdusek in 1990 (Brown et al., 1990) and then developed by Landsbury together with Byron 
Caughey  (Come et al., 1993; Caughey et al., 1995). According to this theory the host PrPc 
can deposit on a polymerisation seed consisting of an infectious PrPSc oligomer. No unfolded 
transition state is needed and, upon deposition, PrPc adopts the specific structure of the seed. 
leading to high molecular aggregates of PrPSc. These aggregates can then  separate again and 
form new seeds. This model also explains the existence of different prion strains, since the 
PrPSc seed can determine the structure of the polymeric aggregates. The conformation does 
not have to be an intrinsic property of the PrP monomer but is induced by the scrapie 
oligomer. These two models, which are not mutually exclusive, are applicable to familial as 
well as infectious manifestations of prion diseases, since the presence of a pathogenic 
mutation presumably favors the spontaneous formation of either PrPSc nuclei or PrP*. 
 
  
PrPc PrP* A 
PrPSc
+  
 
 
B 
 
 
Figure 5. Two models for prion conversion and replication. (A) Heterodimer model; (B) 
the nucleation dependent polymerisation model. 
 
1.8   Prion strains and the species barrier 
Multiple isolates or strains of naturally occurring sheep scrapie have been isolated. Such 
strains differ in their biological properties: they produce distinct incubation periods and 
patterns of neuropathological targets (lesion profiles) in inbred mice and hamsters having the 
same PrP primary sequence. These features are not altered upon cross-species propagation. 
Furthermore, they can be re-isolated in mice after passage in intermediate species with 
different PrP primary structure (Bruce et al., 1994). Two different mink prion strains 
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designated hyper (HY) and drowsy (DY) were serially propagated in hamster and showed 
different biochemical properties as well as specific migration patterns on polyacrylamide gels 
following limited proteolysis. Recently, several human PrPSc types have been identified which 
associate with different phenotypes of CJD (Parchi et al., 1996) (Collinge et al., 1996b). The 
different fragment size seen on Western Blots after PK-treatment suggests that there are 
several PrPSc conformations. Studies done with transgenic mice expressing human PrPc 
showed that different CJD isolated maintained their fragment size and the ratio of the three 
glycolylation isoforms (diglycosylated, monoglycosylated and unglycosylated PrP) (Collinge 
et al., 1996b). Transmission of human and bovine PrPSc to wild type mice resulted in  murine 
PrPSc characterised by the strain phenotype of the inoculum. These data support a model in 
which the strain of the prion, which seems to be encyphered by the conformation of PrPSc, 
conspires with PrPc sequence specified by the recipient to determine the tertiary structure  of 
the nascent PrPSc. For human PrPSc, Collinge and collegues described three types among cases 
of sporadic and iatrogenic CJD and a distinctive fourth pattern for all vCJD cases. Recent 
work has shown that PrPSc conformation may be influenced by binding to metal ions in vitro  
and that different methodologies can lead to discrepancies in the classification of the strain 
types (Wadsworth et al., 1999). 
The transmission of prions between different species is almost always characterised by 
prolonged incubation time during the first passage in the new host when compared to 
transmission within the same species. This prolongation is referred to as “species barrier” 
(Pattison, 1965). De novo synthesised prions reflect the sequence of the host PrP. Upon 
subsequent passage in a homologous host, the incubation time shortens and resembles within-
species transmission. Studies done with transgenic mice have shown that factors contributing 
to the species barrier are the difference in the PrP sequences between the donor and the 
recipient protein, the strain of prion and the species-specificity of the protein-X, a still 
undetermined host factor binding to PrPc and promoting PrPSc formation (Telling et al., 1995; 
Kaneko et al., 1997b). 
The concept of protein X has been introduced to explain the result of experiments with 
transgenic mice expressing both human and mouse PrP (Telling et al., 1995). These mice 
proved to be resistant when inoculated with human prions, whereas mice expressing only 
human PrP could be infected and so were mice expressing mouse PrP and a chimeric mouse-
human PrP. These results were interpreted in terms of a host (mouse) encoded factor (protein 
X) necessary for conversion, which binds to PrPc of its own species with higher affinity than 
to that of a different species thus protecting form conversion by foreign PrPSc. This protein 
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has not been characterised, yet and still remains a merely genetic factor. Whether protein X 
functions as a molecular chaperone participating in the structural transitions during prion 
propagation is still unknown. Possible binding sites for the interaction with protein X have 
been identified at the COOH terminus of PrPc (Kaneko et al., 1997b).  
 
1.9   The N-terminus of the prion protein 
Numerous studies on the conformation of the mature recombinant prion protein revealed a 
properly folded globular structure only limited to the C-terminal domain of the protein, which 
also contains the glycosylation sites and the disulphide bond. In contrast, neither computer 
modelling techniques nor spectroscopic analysis provided evidence for a defined secondary 
structure of the N-terminal part of the PrP encompassing residues 23-120, which displays the 
properties of a random coiled peptide (Riek et al., 1998; Donne et al., 1997; Liemann and 
Glockshuber, 1998). However, since this segment has been seen to contain at least some of 
the binding sites for copper ions, a structured conformation might be acquired in vivo after the 
binding has occurred. Upon conversion of PrPc into PrPSc, residues 23-89 can be digested with 
Proteinase K, whereas the rest of the molecule becomes PK resistant and retains the 
infectivity (Basler et al., 1986; Meyer et al., 1986). The N-terminus of PrP shows a general 
basic character especially in its N-proximal part with four lysines out of eight residues.  
A comparative sequence analysis has evidenced a high conservation of the segment 
encompassing amino acids 23-50 in evolution, where differences between species mainly 
concern insertions and deletions (Wopfner et al., 1999), suggesting a possible function of the 
N-terminus, besides the mentioned copper binding. The role of  the N-terminal part and of the 
octapeptide repeats of the prion protein in the formation of PrPSc was examined in infected 
neuroblastoma cells. Elongation of PrP with extra octapeptides or deletion of amino acids 23-
88 did not alter the synthesis of PrPSc (Rogers et al., 1993). The relevance of the N-terminal 
part of PrPc was also investigated in in vivo studies with mice expressing a transgene 
encoding various truncated PrP molecules (Flechsig et al., 2000). In these studies, deletion of 
residues 23-93 allowed propagation of mouse scrapie in these mice, although with reduced 
levels of detectable PrPSc and altered pathology. These results are in line with in vitro cell-free 
conversion assays performed with hamster PrPc, where the deletion of amino acids 32-94 
reduced the amount of generated protease resistant PrP and showed an alteration in the ability 
of these deletion mutants to bind to PrPSc when compared to wild type PrP (wtPrP) (Lawson 
et al., 2001). Other studies done with N-terminally truncated PrP have suggested that this 
region of the protein might stabilise the C-terminal domain of the molecule or modulate the 
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binding to auxiliary factors participating in the conversion into the pathogenic isoform 
(Zulianello et al., 2000). On the other hand, extra copies of the octapeptide region are 
associated with familial CJD in humans (Owen et al., 1992) and prion disease in transgenic 
mice (Chiesa et al., 2000). 
 
1.10   The Xenopus laevis prion protein 
Recently, a sequence belonging to a portion of the Xenopus laevis prion protein was deposited 
in the EST Database (Washington University Xenopus EST project). Soon afterwards, the 
isolation and characterisation of the whole cDNA sequence of X. laevis PrP was reported 
(Strumbo et al., 2001) together with the deduced amino acid sequence. This represents the 
first amphibian prion protein isolated and is, with its 216 residues, 15 to 20 % shorter than all 
other known PrPs. Comparison of sequences reveals about 28 % identity to mammalian and 
more than 44 % to avian and turtle prion protein. Preliminary analysis of the structural 
characteristics shows a 22 aa long signal peptide followed by a basic region (four lysines out 
of nine residues) similar to the N-proximal part of the mammalian PrP. The main differences, 
when compared to mammalian PrPs, is the absence of the octapeptide repeats whereas 
sequences immediately preceding and following this region show considerable conservation. 
At the C-terminus, the hallmarks of  other PrPs are conserved: an intramolecular disulphide 
bond between two cysteines, two N-glycosylation sites, where the second one probably 
corresponds to an extra glycosylation site present in avian PrPs. The last 22-23 amino acids at 
the C-terminus might represent the signal peptide for the GPI-addition. A model for the three 
dimensional structure of the Xenopus PrP shows three α-helices at the C-terminal part, as seen 
in other species as well as an extra short helix  downstream of the first one. 
 
1.11    The subcellular trafficking of proteins 
In the past years insight has been gained in the understanding of the trafficking of proteins to 
and from the plasma membrane. The transport machinery consists of small membranous 
vesicles.  Newly synthesised proteins are cotranslationally transported into the endoplasmic 
reticulum (ER) where they are properly folded under direction of specific chaperones like 
BiP, Calnexin and Calreticulin, and carbohydrate side chains are added to glycoproteins 
(Matlack et al., 1998). For GPI-proteins, the anchoring step resulting in the addition of the 
GPI moiety to the protein probably occurs in the lumen of the ER. Sorting from the 
endoplasmic reticulum (ER) is an important step in the biosynthetic pathway of secretory and 
membrane proteins. Misfolded or incompletely assembled proteins are subjected to ER 
 18
 Introduction 
__________________________________________________________________________________________ 
associated degradation (ERAD) by the cytoplasmic proteasome, whereas correctly folded 
proteins are incorporated into vesicles and directed to the Golgi stack.  From here, sorting of 
proteins and lipids via several routes to different domains is achieved by the trans-Golgi 
network (TGN), which represents the principal sorting station for targeting of proteins to 
different localisations inside the cell. This organisation is particularly evident in polarised 
cells, where the plasma membrane is divided into functionally distinct domains: the apical and 
the basolateral domains in epithelial cells, the axonal and the dendritic membrane domains in 
neurons. For apical sorting, the sphingolipid- and cholesterol-rich rafts forming in the lumenal 
leaflet of the Golgi membranes work as microdomains for inclusion of proteins destined for 
the plasma membrane (Simons and Ikonen, 1997). 
Sorting of proteins  also characterises endocytosis. Many transmembrane receptors segregate 
into clathrin coated pits before internalisation and from here they are transported to sorting 
endosomes (SEs) and delivered to the recycling endocytic compartment (REC) (Mellman, 
1996; Mukherjee et al., 1997)or recycled to the plasma membrane (Hao and Maxfield, 2000). 
Certain proteins that recycle between the TGN and plasma membrane are delivered to the 
TGN via the endocytic pathway, involving the REC or the mannose-6-phosphate receptor 
pathway. Secretory and endocytic pathway are connected by sorting and separate packaging 
of lysosomal cargo in the Golgi and from the plasma membrane (Hunziker and Geuze, 1996; 
Mallet and Maxfield, 1999). The intracellular fate of GPI-proteins in the endocytic pathway is 
still a matter of debate but seems to be cell type dependent: in Chinese hamster ovary (CHO) 
cells, these proteins were found to be transported to the GPI-proteins enriched endosomal 
compartment (GEEC), probably a sub-compartment of early endosomes and then to 
pericentriolar recycling endosomes before returning to the plasma membrane (Mayor et al., 
1998). In baby hamster kidney cells (BHK) they were transported to early and then to late 
endosomes (Fivaz et al., 2002). The common theme in these sorting processes is the 
recognition of targeting signals. Transmembrane proteins use sequence motifs in their 
cytoplasmic tails (for instance tyrosine or dileucine based motifs), which are recognised by 
specific sorter or adaptor proteins (Bonifacino and Dell'Angelica, 1999; Matter, 2000). 
For proteins lacking cytoplasmic domains sorting to specific cellular destinations is not 
exclusively based on protein sequence: N- and O-linked glycosylations can act as sorting 
determinants (Scheiffele et al., 1995). Lipid attachment (e.g. palmitoylation) can also serve as 
a targeting signal in cooperative protein-lipid affinities (Zhao et al., 2000). In line with these 
results, several studies have shown that the GPI-anchor can act as a component in a targeting 
signal in polarised cells (Brown et al., 1989; Lisanti et al., 1989). Of note, for some proteins 
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the N-terminal stretch was reported to contain a plasma membrane localisation determinant 
(Lecat et al., 2000). 
 
 
Figure 6: Sorting steps for the biosynthetic 
(thick open arrows) and endocytic (thin solid 
arrows)  pathways. 
 
LE: late endosomes; Lyso: lysosome; REC: 
recycling endocytic compartment; CCP: clathrin 
coated pits 
 
 
 
 
 
 
 
 
 
 
 
1.11.1   Subcellular trafficking of the prion protein 
Studies on the intracellular trafficking of the cellular prion protein have revealed that, 
following transport through the secretory pathway, the protein is present at the cell surface 
one hour after synthesis (Caughey et al., 1989). Further work done with chicken PrP reported 
rapid endocytosis of PrPc and cycling between the cell surface and endocytic compartments 
(Shyng et al., 1993) before degradation in lysosomes with a half life of 3-6 hours (Caughey et 
al., 1989; Borchelt et al., 1990). Other studies on the endocytosis of PrPc reported that its 
internalisation  might be conditioned by metal ions binding to the octapeptide region 
(Sumudhu et al., 2001). 
Mutations and deletions characterising various forms of familial prion diseases often lead to 
misfolding and mistrafficking of PrP. Some of these mutants are partially retained in the ER 
and subjected to the quality control mechanisms of the cell and to degradation by the 
proteasome (Zanusso et al., 1999; Stewart et al., 2001). Studies done with PrP constructs 
lacking the GPI-anchor revealed slower transport through the secretory pathway when 
compared to wild type PrPc (wtPrPc)  (Walmsley et al., 2001), although conversion of these 
constructs into PrPSc was previously not found significantly compromised (Rogers et al., 
1993). Prevention of glycosylation affected the transport to the cell surface and changed the 
biochemical properties of PrPc (Taraboulos et al., 1990a; Lehmann and Harris, 1997). 
Addition of a transmembrane moiety to the C-terminus of PrPc has been shown to affect 
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subcellular trafficking and to inhibit conversion into the scrapie isoform (Taraboulos et al., 
1995).  
 
1.12    Aim of this work 
This study aimes at devising a physiological function to the unstructured N-terminal part of 
PrPc in subcellular trafficking. Expression of wild type mouse PrP, of specific N-terminally 
truncated mouse prion proteins and of one chimeric Xenopus laevis-mouse PrP construct in 
murine neuroblastoma cells allowed further characterisation of the intracellular trafficking 
and turn-over of the prion protein. Metabolic labelling techniques and surface-biotinylation 
assays were performed in order to follow the internalisation from the exofacial plasma 
membrane, the transport along the secretory pathway in a comparative analysis. These results 
provide deeper insight into the life-cycle of the cellular prion protein, raising the novel 
possibility of a targeting function of its N-proximal part by interacting with the secretory and 
the endocytic machinery. They also indicate the conservation of this targeting property in 
evolution. 
Numerous attempts have been undertaken in animal and cell-culture models in order to 
interfere with conversion of PrPc into infectious PrPSc (Aguzzi et al., 2001). Several 
compounds analysed for their properties to interfere with this fundamental step in the 
propagation of prions seem to modulate the subcellular trafficking of PrP (Shyng et al., 
1995a; Gilch et al., 2001). Characterisation of the cellular life-cycle of the prion protein and 
of the mechanisms underlying this process is therefore important in order to be able to 
optimise strategies leading to effective interference with prion propagation. 
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2 Material and methods 
 
2.1   Antibodies 
 
The following antibodies were used for detection of wtPrPc and PrP mutants in immunoblot 
assay, immunoprecipitations or FACS analysis: 
 
Primary antibodies 
Name Specificity  Origin  Company  
3F4 3F4 epitope (residues 
109-112 in human 
PrP) 
Mouse monoclonal  Signet Pathology 
System, USA 
A7 Prion protein Rabbit polyclonal Our laboratories  
 
Secondary antibodies  
Name Specificity Origin Company 
Peroxidase - labeled 
IgG 
Anti-mouse Sheep Amersham Pharmacia, 
Freiburg 
Peroxidase - labeled 
IgG 
Anti-rabbit Donkey Amersham Pharmacia, 
Freiburg 
Fluorescein - 
Isothyocianate 
(FITC)- linked IgG 
Anti-mouse Donkey Dianova, Hamburg 
 
 
2.2   DNA cloning   
 
2.2.1 Polymerase chain reaction (PCR)  
       
Oligonucleotides      Metabion (Germany) 
MWG  (Germany) 
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Deoxynucleotide 1 mM each  dATP, dTTP, dGTP, 
dCTP (Amersham Pharmacia, 
Freiburg, Germany) 
 
DNA polymerase Taq  Gold (Roche Diagnostic, 
Mannheim), 
Pfu Turbo (Stratagene, The 
Netherlands)  
10x PCR reaction buffer      Roche Diagnostic, Mannheim; 
        Stratagene, The Netherlands 
      
 
Polymerase chain reaction procedure was used to amplify specific  DNA sequences in vitro. A 
50 µl reaction was set as follows: 
 
DNA template       50-100 ng  
5´ primer       2 µl (100 nM) 
3´ primer       2 µl (100 nM) 
dNTP-mix       50 µM   
Polymerase       10 units 
10 x polymerase reaction buffer    10 % volume 
Aqua dest.       ad 50 µl 
 
Reaction mix was set in 0.5 ml reaction tubes and was carried out in a PE 9600 Thermocycler 
(Perkin Elmer). The temperature for hybridisation of oligonucleotides with single strand 
parental DNA (Annealing) was generally set at 55° C. For more specific reactions the 
temperature was adjusted according to the following formula: 
TA (°C) = 60+ [(G+ C) x 41/ Nt] – (600/ Nt) 
where TA represents the annealing temperature, C+G the amount of guanine and cytosine in 
the primary sequence of the priming nucleotide and Nt the length (number of nucleotides) of 
the primers). 
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Amplification parameters: 
95° C      5-10 min initial denaturation (once) 
35 cycles with: 
95° C      1 min amplification 
55° C (or required T)    1 min annealing temperature  
72° C      1,5 min elongation 
 
72° C      7 min final elongation (once) 
 
Amplified DNA fragments were loaded on agarose gels for electrophoresis and purification. 
 
PCR primers Sequence (5´-3´) 
PrP Bam HI 1 fwd GCG GAT CCG TCG CCA CCA TGG CGA ACC TTG GCT A 
PrP Eco RI 254 rev  ATC GAA TTC ATC ATC CCA CGA TCA GGA AGA 
PrP Eco RI 91 fwd GCG AAT TCG GAG GGG GTA CCC ATA ATC AG 
PrP Eco RI 66 rev GCG AAT TCT TGT CCC CAG CCA CCA CCG TG 
PrP Pst I 22 rev GCC TGC AGG CAG AGG CCA ACA TCA GTC C  
PrP Pst I 90 fwd CAC TGC AGC AAG GAG GGG GTA CCC ACA ATC 
PrP Kpn I 48 fwd  AGC CCT GGA GGC AAC GGT ACC CAC CTC AGG GTG 
PrP Kpn I 48 rev CAC CCT GAG GTG GGT ACC GTT GCC TCC AGG GCT 
PrP Pst I 51 fwd CAC TGC AGG GTG GCA CCT GGG GGC AG 
PrP Xba I 91 fwd CGC TCT AGA GGA GGG GGT ACC CAT AAT CAG 
Xen PrP Pst 23 fwd CGC CTG CAG AAG AAG AGC GGT GGT GGG AAA 
Xen PrP Xba I 69 rev CGC TCT AGA CCT GTT ATA ACC GCT AGG ATT 
Sequencing Primers  
PcDNA 3.1 + CTA TAT AAG CAG AGC TCT C 
PcDNA 3.1 - TAG AAG GCA CAG TCG AGG 
T7 TAA TAC GAC TCA CTA TAG GG 
M13 fwd GTA AAA CGA CGG CCA G 
M13 rev CAG GAA ACA GCT ATG AC 
MHM2 GAA GCA TAT GGC AGG TGC T 
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2.2.2 Agarose gel electrophoresis 
 
Agarose      Gibco/ BRL Life Lab., Paisley, Scotland 
 
TAE- buffer      40 mM Tris-Acetate 
       1 mM EDTA, pH 8.0 
 
5x loading buffer     50 % glycerol in TAE- buffer 
0.05 % bromphenol blue 
 
100 base pair DNA ladder     Gibco/ BRL Life Lab., Paisley, Scotland
     
 
Agarose gels (0.5 to 2 % depending on the length of the DNA fragment) were prepared by 
dissolving agarose in TAE-buffer by boiling the buffer in a microwave. After the solution had 
cooled to ca. 60° C, 1.5 µl ethidium bromide were added and the mixture was transferred into 
the appropriate gel chamber for solidification. The gel was then covered with TAE buffer and 
DNA samples to which the sample buffer had been added as well as 1,5 µl of the DNA ladder 
marker were loaded onto the gel. The gel was run under constant voltage (110V) in order to 
separate DNA fragments. After the electrophoresis, the ethidium-bromide-stained DNA was 
visualised under the UV-light and photographed with an “eagle eye” processor (Stratagene, 
The Netherlands).    
 
2.2.3 Isolation and elution of DNA fragments from agarose gel  
 
After electrophoresis separation, agarose gel fragments were excised from the gel with a 
scalpel and eluted to 20-50 µl in water using  GFXTM Purification Kit (Amersham Pharmacia, 
Freiburg, Germany) according to manufacturer ´ s procedures.   
 
2.2.4 Enzymatic digestion of DNA 
 
Restriction endonucleases    New England Biolabs, USA 
10 x reaction buffer     New England Biolabs, USA 
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Restriction enzymes were used for DNA digestion applying the recommended  buffers in a 20 
or 40 µl final volume. 1-3 µg DNA were usually digested with at least 10 units of the required 
enzyme, either for 2 h or over night at 37° C. 
 
 
2.2.5 DNA dephosphorylation 
 
Treatment of digested DNA with alkaline phosphatase (calf intestinal phosphatase, CIP, NEB) 
which catalyses the removal of 5´ phosphate groups was carried out in order to prevent self-
re-circularisation of the plasmide vector. The reaction was set by adding 0.1 units CIP/ pmol 
DNA and 1 X CIP buffer to the digested DNA. The reaction mixture was incubated at 37° C 
for 1 h. 
 
2.2.6 Ligation 
 
Vector and DNA fragments were ligated with a molecular ratio of 1:3 using either the T4- 
ligase (Gibco/ BRL Life Lab., Paisley, Scotland) or the DNA Quick Ligation Kit (Roche 
Diagnostic, Mannheim). For ligation with T4-ligase, the 10 x ligation buffer and 1 unit of the 
ligase were used in a total volume of 20 µl and the reaction mixture was incubated over night 
at 16 ° C. Ligation with the Quick Ligation Kit was carried out according to manufacturer´s 
procedures and the reaction was incubated at room temperature for 8-9 min. 
 
2.2.7 DNA sequencing  
 
10 x TBE buffer     0.9 M Tris 
       0.9 M boric acid 
       0.02 M EDTA 
 
The reactions were set using  the ABI PRISMTM Taq DyeDeoxyTerminator Cycle Sequencing 
Kit (Perkin Elmer) according to manufacture´ s directions. 100 ng of isolated  PCR fragments 
or 1µg of plasmid DNA were used for the reaction in a GeneAmP PCR 9600 thermal cycler 
(Perkin Elmer). The amplification was carried out as follows: 
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96° C 15´´ 
50° C 15´´ 
60° C   4´ 
25 cycles 
 
The DNA was precipitated with 1/10 Vol. Na-Acetate (1.5 M, pH 5.2) and 2.5 Vol. EtOH (96 
%) and was then centrifuged for 30 min at room temperature. The precipitate was  washed 
with 70 % EtOH and centrifuged again for 10 min. The pellet was dried and dissolved in the 
appropriate buffer and run on an ABI 373 DNA-Sequencer (Perkin Elmer) and analysed with 
a specific software. Five % polyacrylamide sequencing gel was prepared as follows: 
 
30 g urea 
16 ml 30 % (w/ v) acrylamide/ bisacrylamide (37.5:1) (National Diagnostics, Atlanta, USA) 
6 ml 10 TBE buffer 
22 ml H2O 
 
2.2.8   Preparation of Heat Shock competent bacteria  
 
SOC medium      2 % Trypton 
       0.5 % Bacto yeast extract 
       10 mM NaCl 
       2.5 mM KCl 
       10 mM MgCl2 
       10 mM MgSO4 
       20 mM glucose 
 
200 ml LB medium were inoculated with one colony from an LB agar plate and transferred to 
a shaking incubator at 37° C until an OD600  of 0.6-0.7 was reached. The bacterial culture was 
placed on ice for 15 min. After centrifugation at 3000 g for 15 min at 4° C the pellet was first 
suspended in 50 ml ice cold 100 mM MgCl2 , placed on ice again for 30 min and then, after a 
new centrifugation step suspended in 50 ml cold 100 mM CaCl2. and placed on ice for 30 min 
Bacteria were pelletted again and incubated overnight in 5 ml CaCL2 at 4° C. 0.5 ml glycerol 
and 2.5 ml CaCl2 were added and 100 µl aliquots were stored at –80° C. 
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2.2.9  Heat shock transformation 
 
Heat shock competent E. coli (100 µl aliquot) were thawed on ice and up to 1 µg plasmid 
DNA or ligation mixture (max. 10 µl) were added and incubated on ice for 30 min. Bacterial 
cells were then warmed to 42° C for 90 sec and immediately chilled on ice for 2 min. 400 µl 
SOC medium was added and the bacteria were transferred to a shaking incubator set at 37° C 
to allow the bacteria to recover and to express the antibiotic resistance. After incubation for 
30 min, the cultures were plated onto an LB agar plate with the appropriate selective 
antibiotic and incubated at 37° C overnight.  
 
2.3   DNA extraction and purification  
 
2.3.1   Small scale preparation of plasmid DNA from bacteria (Minipreparation) 
 
Solution I     10 mM EDTA, 400 µg/ ml RNase I 
      100 mM Tris-HCl, pH 7.5 
 
Solution II     1 M NaOH 
      5.3 % dodecyl sulfate sodium salt (SDS) 
 
Solution III     Buffered solution containing acetate 
 
For isolation of plasmid DNA from bacterial culture, the GFX Micro Plasmid Prep Kit 
(Amersham Pharmacia, Freiburg, Germany) was used according to manufacturer´ s directions. 
1.5 ml of an overnight bacterial cell culture were pelletted in a microcentirfuge tube and 
suspended in an isotonic solution containing RNA (Solution I). Cells were then lysed by 
alkali treatment, chromosomal DNA and proteins were denatured with addition of solution II. 
The pH of the solution was neutralised with an acetate solution (Solution III) and cell debris, 
chromosomal DNA and proteins were precipitated. After centrifugation, the supernatant cell 
lysate was transferred to a GFX glass fiber matrix matrix column  to bind plasmid DNA. The 
matrix bound DNA was washed  with an ethanolic buffer to  remove salts and other residual 
contamination. The DNA was eluted  from the matrix  in 100 µl sterile bidest. water. The total 
yield of DNA was between 1 and 5 µg. 
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2.3.2   Large scale preparation of plasmid DNA from bacteria (Maxipreparation) 
 
Resuspension buffer (P1)     50 mM Tris/HCl, pH 8.0 
        10 mM EDTA 
        100 µg/ ml RNase A 
Lysis buffer (P2)      2 mM NaOH, 1% SDS (w/v) 
Neutralisation buffer      3.0 M potassium acetate, pH 5.5 
 
Equilibration buffer (QBT)     750 mM NaCl 
        50 mM MOPS 
        15 % (v/ v) EtOH 
        0.15 % (w/ v) Triton X-100 
Wash buffer (QC)      1 M NaCl 
        50 mM MOPS 
        15 % (v/v) EtOH 
        pH 7 
Elution Buffer  (QF)      50 mM Tris/ HCl, pH 8.5 
        1.25 M NaCl 
        15 % (v/ v) EtOH 
  
For purification of up to 500 µg plasmid DNA from bacterial culture, 2 ml of an overnight 
clone culture were diluted into 100 ml selective LB medium and were grown overnight at 37° 
C.  After pelletting the cells  at 4000 g and 4° C for 15 min, the commercially available 
Quiagen Maxi Purification Kit was applied according to manufacture´s direction. The 
protocol is based on  an alkaline lysis procedure, followed by binding of plasmid DNA to an 
anion exchange resin columns under low salt condition. The DNA was eluted,  concentrated 
and desalted by isopropanol precipitation. The pellet was dissolved in sterile H2O dest.  
 
2.3.3 Spectrophotometric determination of amount of DNA  
 
DNA was diluted 1:20 in H2O and its concentration was measured in a spectrophotometer 
(Beckmann). DNA shows a maximum absorbation at 260 nm which allows calculation of 
DNA concentration. The reading was also taken at a wavelength of 280 nm since the ratio 
between  these two values (OD260/ OD280) provides an estimation of purity of the nucleic acid. 
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For pure preparation of DNA this value should be 1.8.Values higher than 1.8 indicate 
contamination with proteins.  
 
2.4   Culture of bacterial cells 
 
2.4.1   Bacterial cells used in this work 
 
For amplification of plasmids E. coli bacterial strains XL1, Top 10 or DH5α were used. 
 
2.4.2 Growing of bacterial cells 
 
LB medium/agar 
bacto trypton    10 g 
bacto yeast extract    5 g 
NaCl                 10 g 
bacto agar   15 g 
ad 1 l with aq. dest. 
ampicillin   500 µg/ ml 
(Sigma, Munich) 
 
kanamycin monosulfate 500 µg/ ml 
(Sigma, Munich) 
 
For isolation of single colonies bacterial suspensions were plated on a Petri dish with solid 
LB-medium containing the appropriate antibiotic. Single bacterial colonies were grown in 
autoclaved LB-medium after addition of the adequate antibiotic to the medium for selection. 
Growing of bacteria was achieved by growing cultures overnight (at least 8 hours) at 37° C in 
a shaking incubator until an OD600 between 0.6 and 0.8 was reached. LB- solid and liquid 
medium share the same ingredients, the difference being the addition of 15 g/l Agar for the 
solid medium. 
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2.4.3   Determination of  cell density  
 
The number of cells in the growing culture was monitored by measurement of the optical 
density at a wavelength of  600 nm in 1.5 ml plastic cuvettes, culture medium was used as a 
control. 
 
2.4.4  Storage of bacteria 
 
For storage of bacteria, 1 ml  aliquots from a liquid culture (OD600 ca.0.8) were added to 400 
µl glycerol and preserved in 1.5 ml storage tubes equipped with screw caps and stored at –80° 
C. 
 
2.5  Working with mammalian cells 
 
2.5.1 Mammalian cell lines used in this work 
 
N2a (ATCC CCL 131) murine neuroblastoma (Butler et al., 1988) 
 
2.5.2 Culture media  
 
DMEM, Dulbecco´s modified Eagle medium 
(Gibco/ BRL Life Lab., Paisley, Scotland) 
supplemented with       2 mM L-glutamin 
        100 IU/ml penicillin 
0.1 mg/ ml streptomycin 
10 % (v/v) fetal calf serum (FCS) 
(inactivated at 56° C for 30 min) 
 
Optimem        100 IU/ml penicillin 
(Gibco/ BRL Life Lab., Paisley, Scotland)    0.1 mg/ ml streptomycin 
10 % (v/v) fetal calf serum (FCS) 
(PAA, Marburg) 
(inactivated at 56° C for 30 min) 
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Trypsin-EDTA 
(Gibco/ BRL Life Lab., Paisley, Scotland)   0.25 % trypsin, 1 mM EDTA- 4Na  
Phosphate buffered saline (PBS)  
(Gibco/ BRL Life Lab., Paisley, Scotland) 
 
2.5.3 Culture of mammalian cells 
 
Cells were cultivated on appropriate culture dishes (NUNC) and kept in an incubator in a 5 % 
CO2, 90 % humidity atmosphere at 37° C.  Medium was changed every two days. When 80 % 
confluency was reached, cells were washed with PBS, briefly treated with 1 ml trypsin-EDTA 
in order to remove cells from the dish. Cells were then suspended in culture medium and 
transferred to a new culture dish in a 1:10-1:20 volume ratio, unless otherwise specified.  
 
2.5.4 Storage of  eukaryotic cells 
 
Dimethyl sulfoxide (DMSO)      Sigma, Munich 
 
For storage of mammalian cells, 75-80 % confluent adherent cultures were subjected to mild 
treatment with trypsin and suspended in culture medium with addition of  20 % total FCS and 
10 % DMSO. 1 ml aliquots of the suspension were transferred to 1.5 ml cryotubes (NUNC) 
and frozen  to –80° C for 24 h. Tubes were then transferred to liquid nitrogen for long-term 
storage. Thawing was achieved by incubating frozen cells at 37° C for 10-15 min. Cells were 
resuspended in 10 ml culture medium with 10 % FCS and centrifuged for 10 min at 1000 g in 
order to remove toxic DMSO. The supernatant was removed and the pellet resuspended in 10 
medium and plated on culture dish. 
 
2.5.5   Transient transfection of  mammalian cells  
 
Transfection with Superfect (Qiagen, Hilden) 
Activated dendrimeric polyamides function as carriers for introduction of plasmid DNA into  
the mammalian cell membrane. On day of transfection cells were 50 % confluent. The 
Superfect tranfection reagent was added to the cells according to manufacturer ´ s directions, 
medium was changed after 4 h and cells were lysed after 72 h for analysis. 
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Transfection with Effectene (Qiagen, Hilden) 
Effectene is a non-liposomal transfection reagent coating DNA into micelle structures which 
are then transferred into eukaryotic cells. 40- 80% confluent cells. Generally, 2 µg DNA were 
used to transfect 50-60 % confluent cells following the recommended protocol. DNA is first 
condensed by interaction with an enhancer, Effectene reagent is then added to produce a 
complex with the DNA which is mixed with the medium and then added to the cells. 
 
Transfection with Fugene 6 (Roche Diagnostic, Mannheim) 
Fugene 6 transfection reagent is a blend of lipids and other components supplied in 80 % 
ethanol. Standard transfection was performed by dissolving 2 µg DNA in serum-free medium. 
Transfection reagent was then added and the mix was incubated at room temperature for 15 
min before adding to the cells. 
 
2.6   Internalisation assay with cell surface biotinylation 
 
Sulfo-biotin-X-NHS (Pierce)     250 µ/ml 
 
Lysis buffer       100 mM NaCl 
        10 mM Tris-HCl, pH 7.5 
        10 mM EDTA 
        0.5 % Triton X-100 
        0.5 % DOC 
 
Endocytosis of wtPrPc and PrP mutants located on the cell surface was assessed by surface 
biotinylation. N2a cells were plated on 6 cm Petri dishes and transiently transfected. After 72 
h, cells were placed on ice, washed twice with cold PBS and incubated on  ice for 15 min with 
1 ml PBS containing 250 µg sulfo-biotin-X-NHS. Cells were then washed again 3 times with 
cold PBS to remove unbound biotin and were either harvested directly with 1 ml cold lysis 
buffer on ice for 10 min or cultured for appropriate chase times as indicated for each 
experiment in the presence of complete medium at 37 °C to allow internalisation. Cells were 
then washed with PBS and either lysed directly or treated with 1 ml Trypsin-EDTA on ice for 
10 min before lysis and immunoprecipitated as described above, using  mAb 3F4 for detection 
of transfected constructs. Immunoadsorbed proteins were finally subjected to 12.5% SDS-
PAGE and transferred to PVDF membranes (Amersham Pharmacia, Freiburg, Germany) for 
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electrophoresis. After blotting and blocking of unspecific binding sites in skim milk buffer, 
the membrane was incubated with 1:5000 horseradish peroxidase-conjugated streptavidin in 
TBST for 1 h at room temperature and visualised with enhanced ECL plus 
chemoluminescence kit (Amersham Pharmacia, Freiburg, Germany).  
 
 
2.7   Metabolic labelling and radio-immunoprecipitation  
 
Cys/ Meth-free medium  RPMI without cysteine or methionine 
(Gibco/ BRL Life Lab., Paisley, Scotland) 
with 1% FCS 
 
 
[35S]- cysteine and methionine Promix  L-[35S]- in vitro Cell labelling mix 
1000 Ci/mmol (Amersham Pharmacia, 
Freiburg) 
 
Chase medium      complete culture medium with 10 % FCS 
 
Lysis buffer      100 mM NaCl 
       10 mM Tris-HCl, pH 7.5 
       10 mM EDTA 
       0.5 % Triton X-100 
       0.5 % DOC    
   
RIPA buffer-SDS     0.5 % Triton X-100 
       0.5 % DOC 
       1% SDS 
       in PBS 
        
Protein A- sepharose     50 % suspension in RIPA buffer-SDS 
(Amersham Pharmacia, Freiburg) 
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Pefabloc protease inhibitor  1 % stock solution 
 (Roche Diagnostic, Mannheim) 
     
  
 
 
For immunoprecipitation transiently transfected  N2a cells (6 cm Petri dishes) with 80-90 % 
confluency were used. Cells were washed twice with phosphate-buffered saline (PBS) and  
placed into an incubator at 37° C for 1 h in the presence of 1 ml RPMI medium without 
methionine/cysteine containing 1% FCS to promote metabolism of endogenous methionine 
and cysteine. Subsequent radioactive labelling of proteins was carried out by adding 400 
µCi/ml [35S]-Met/Cys to the medium for 5 min or, for half-life studies, for 1 h, respectively, at 
37° C (pulse). After incubation, cells were washed twice in cold PBS and harvested with 1 ml 
lysis buffer on ice for 10 min or further incubated at 37 °C  for different lengths of time  in 5 
ml complete culture medium to allow transport to the cell surface (chase). After appropriate  
chase times, cells were washed with PBS and either directly harvested or subjected to mild 
trypsin digestion. 1 ml Trypsin-EDTA was added to the dishes for 10 min on ice. Trypsinised 
cells were transferred to 15 ml poly-propylene tubes and the reaction was stopped by 
centrifugation of the cells twice at 900 x g in PBS containig 20% FCS and 100 µl Trypsin 
inhibitor. After lysis, cell lysates were transferred to 1.5 ml tubes and debris was removed by 
centrifugation for 40 sec at 18000 g. After addition of 1% N-lauryl sarcosine, postnuclear 
lysates were boiled at 95 °C for 10 min. Samples were placed on ice and 20 µl Pefabloc 
protease inhibitor were added; lysates were then incubated with antibody A7 or 3F4, as 
indicated, overnight at 4 °C (dilution 1:300). The protein-antibody complexes were 
precipitated by addition of 100 µl protein A-Sepharose beads for 90 min at 4 °C. The beads 
were then centrifuged at 18000 g for 1 min and washed in RIPA buffer supplemented with 1 
% SDS at 4 °C. The washing procedure was repeated five times. All samples were treated 
with 0.1 units/µl PNGase F  at 37 °C overnight to remove N-linked oligosaccharides and 
analysed by 12.5 % SDS-PAGE after elution with 4x sample buffer and boiling for 10 min at 
95° C. SDS- ployacrylamide gels containing proteins radiolabelled with 35S-labelled amino 
acids were subsequently fixed in blotting buffer for 15 min before placing on Whatman paper 
and fitting on a gel for 2  h at 80° C. Dried gel was then placed in a light-tight X-ray holder 
and covered with a sheet of X-ray film (Kodak biomax MR). The film holder was stored at –
80 °C for the appropriate length of time and then developed with an automatic film processor. 
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2.7.1 Trypsin digestion  
 
Trypsin-EDTA     (Gibco/ BRL Life Lab., Paisley, Scotland) 
 
Trypsin inhibitor     stock solution 50 mg/ ml 
(Sigma, Munich) 
 
In order to separate intracellular from surface located proteins, 1 ml Trypsin-EDTA was 
added on the cultured cells before lysis  for 10 min on ice. Trypsinised cells were transferred 
to 15 ml poly-propylene tubes and the reaction was stopped by centrifugation of the cells 
twice at 900 x g in 5 ml PBS containing 20% FCS and 100 µl Trypsin inhibitor. Centrifuged 
cells were then resuspended in 1 ml lysis buffer for lysis on ice.  
 
2.7.2 Treatment with Endoglycosidase-H (Endo-H) 
 
β-Mercaptoethanol/SDS for Endo-H   0.1 M β-Mercaptoethanol 
0.1 % (w/v) SDS 
 
Endo-H buffer     0.1 M Na-citrate pH 5.5 
       0.5 % PMSF (protease inhibitor) 
6 mU Endo-H 
 (Roche Diagnostic, Mannheim)  
 
For Endo-H digestion of glycoproteins, immunoprecipitated proteins were incubated with  50 
µl 0.1 M 2-mercaptoethanol/ 0.1% SDS and heated at 95 °C for 10 min. Samples were then 
centrifuged at 18000 g for 2 min and supernatants were divided into two halves: one aliquot 
was supplemented with 25 µl Endo-H buffer containing 10 mU Endo-H, the other half was 
incubated with buffer without Endo-H. All samples were stored overnight at 37 °C, then 
subjected to SDS-PAGE after addition of 4x sample buffer. 
        
2.7.3   Digestion with N-Glycosidase F (PNGase F)  
 
Et-SH/ SDS      0.1 M Mercaptoethanol 
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       0.5 % SDS 
 
PNGase F buffer     20 µl lysis buffer (post-nuclear) 
(1 sample)      2.5 µl Pefabloc (1 %) 
2.5 units PNGase F  
(Roche Diagnostic, Mannheim) 
      
PNGase F treatment was carried out by re-suspending immunoprecipitated proteins in 20 µl 
Et-SH/ SDS and heating at 95 °C for 10 min. Supernatants were incubated with 25 µl PNGase 
F buffer overnight at 37 °C prior to analysis on SDS-PAGE. For Western blot, 200 µl post-
nuclear lysates were boiled in the presence of Et-SH/SDS, then 10 µl Pefabloc (1 %) and 5 
units PNGase F were added end the reaction mixture was incubated overnight at 37° C. 
Samples were precipitated with methanol and prepared for SDS-PAGE as described below. 
 
2.8   Preparation of postnuclear lysates  
 
Lysis buffer      100 mM NaCl 
       10 mM Tris-HCl, pH 7.5 
       10 mM EDTA 
       0.5 % Triton X-100 
       0.5 % DOC 
 
TNE       50mM Tris/HCl pH 7.5 
       150 mM NaCl 
       5 mM EDTA 
 
4 x SDS sample buffer    7 % SDS  
       30 % glycerol  
       20 % β-mercaptoethanol 
        0.01 % bromphenol blue  
        90 mM tris/ HCl pH 6.8 
 
Pefabloc SC (AEBSF)    1 % stock solution   
(Roche Diagnostic, Mannheim) 
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Adherent cells were washed once with PBS and were subsequently covered with 1 ml lysis 
buffer at room temperature for 10 min. Total lysates were transferred to 1.5 ml reaction tubes 
for separation of cell debris by centrifugation for 40 sec at 14.000 rpm. 20 µl of the 1 % 
Pefabloc stock solution were added to the supernatants before precipitation with 10 vol. 
methanol overnight  at –20° C or  -80° C for 2 h. Samples were then centrifuged at 3500 rpm 
for 30 min at 4° C and the resulting pellet was resuspended in  50-100 µl TNE and 4x SDS- 
sample buffer was added. Samples were heated o 95° C for 10 min and placed on ice. 
 
2.8.1   Detergent solubility assay  
 
N-lauroyl sarcosine      10 % stock solution 
(Sigma, Munich) 
 
Post-nuclear cell lysates were supplemented with 0.5 mM Pefabloc protease inhibitor and N-
lauryl sarcosine to 1 %, and centrifuged for 1 h at 100 000 g and 4 °C in a Beckman TL-100 
centrifuge. Soluble fractions (supernatant) were precipitated with ethanol as described above. 
Insoluble fractions (pellet) were resuspended in 50 µl TNE. Ethanol precipitated samples 
were centrifuged for 30 min at 3500 g, the pellets redissolved in TNE buffer with addition of 
SDS-loading buffer. Samples were analysed on 12.5 % SDS-PAGE.  
 
2.8.2 Proteinase K (PK) digestion 
 
Proteinase K (PK)      1 mg /ml stock solution 
(Merck, Darmstadt) 
 
Aliquots of post-nuclear lysates were incubated for 30 min at 37 °C with 20 µg/ml PK; the 
digestion was stopped by addition of protease inhibitor Pefabloc. Samples were precipitated 
with ethanol and analysed in immunoblot assay. 
 
2.8.3 SDS-PAGE 
 
4 x Resolving solution     1.5 M Tris  
        0.4 % SDS 
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       pH ad 8.8 
      
      
 4 x Stacking solution     0.5 M Tris 
       0.4 % SDS 
       pH ad 6.8 
Ammoniumpersulfate (APS)    10% (w/ v) stock solution   
 
N,N,N,N-tetramethylethylendiamin (TEMED) Pharmacia/ LKB, Upplasa, Sweden 
 
Resolving gel 25.9 ml 30 % (w/ v) acrylamide/ 
bisacrylamide (37.5:1) Protogel 
(National Diagnostics, Atlanta, USA) 
(12.5 % acrylamide)     15.4 ml resolving solution 
       20.3 ml aqua dest. 
90 µl TEMED     
192  µl 10% (w/ v) ammoniumpersulfate 
(APS) in H2O 
 
Stacking gel 2.8 ml 30 % (w/ v) 
acrylamide/bisacrylamide (37.5:1) 
(5 % acrylamide)     4.2 ml stacking solution 
       9.9 ml aqua dest. 
       30 µl TEMED 
       168 µl 10% (w/ v) APS 
 
 
10 x SDS electrophoresis buffer   250 mM tris 
       2.5 M glycine 
       1 % SDS 
 
Electrophoresis separation of proteins was carried out on denaturing SDS gels containig 12.5 
% acrylamide (Laemmli, 1970). After polymerisation was completed, the glass plates 
containing stacking and resolving gels were mounted in an electrophoresis chamber and 
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covered with electrophoresis buffer. Samples were loaded on the gel (15-25 µl). Constant 
voltage (27 or 45 depending on the size of the gel) was applied for mass separation until the 
proteins had reached the bottom of the resolving gel. 
      
2.8.4  Western blot 
 
Blotting buffer     20 % methanol 
       3 g Tris 
       14.5 g glycine 
       
 
10 x TBST      0. 5 % tween 20 
       100 mM NaCl 
       10 mM Tris/ HCl pH 7.4 
       
Skim milk buffer   5 %  (2.5 g) skim milk powder (Merk, 
Darmstadt) 
       in TBST buffer (ad 50 ml) 
 
PVDF membrane     Amersham Pharmacia Freiburg, Germany 
 
Semi-Dry transblot machine     Bio-Rad, Richmond, USA 
 
Detection kit ECLPLUS Western Blot Detection kit      
Amersham Pharmacia, Freiburg, Germany 
 
X-ray films      Kodak Biomax XS 
 
After electrophoretic mass separation, proteins were electro-transferred from polyacrylamyde 
gels onto a Hybond-P:PVDF membrane using a semi-dry-methode. The membrane was 
activated with mehanol and then equilibrated with dest. water. Gel was palced in contact with 
the membrane. They were then sandwiched together between 6 layers of Whatman paper 
which had been soaked in Blotting Buffer. A Semi-Dry Transblot electrophoresis apparatus  
was used for the transfer, a current of 2 A was applied for 30 min or 45 min (depending on the 
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size of the gel). The membrane was then incubated  in 5% skim milk buffer for 30 min at 
room temperature for saturation of unspecific binding sites and then in TBST with the specific 
primary antibody and shaken overnight at 4° C. The membrane was washed 5 times (5 min 
each) with TBST and the secondary antibody (peroxidase conjugated) was subsequently 
added to TBST at a dilution of 1:7500 for 30 min. The membrane was washed again 3 times 
with TBST, finally with dest. water. The antibody-  
protein complex was visualised with an enhanced chemoluminescence ECL-plus kit by 
incubating the membrane for 2 min in the ECL-solution (solution 1:solutioin 2: 1:40), drying 
it with Whatman paper and exposing it to X-ray films. 
 
2.9   Detection and evaluation of radioactive signals 
 
The autoradiographic signals were quantified by Phosphor Imager analysis of the gel 
(Molecular Dynamics). The amount of  total or intracellular (after surface trypsin digestion) 
PrP present at each time point after the chase was expressed as percentage of  nascent PrP 
rescued from the cell lysate directly at the end of the labelling period.  
 
2.10   Detection and evaluation of non-radioactive signals (densitometric analysis) 
 
Films were digitised using an APB Image Scanner and images quantified using Image Master 
1D software (both Amersham Pharmacia Biotech). 
 
2.11   Treatment of cells with lysosomal inhibitor Leupeptin  
 
Leupeptin       1 mg/ ml stock solution 
(Roche Diagnostic, Mannheim) 
 
For inhibition of lysosomal degradation the serine and thiol protease inhibitor leupeptin  was 
added to cultured cells for 24 h. The inhibitor was dissolved in aqua dest. and added to culture 
medium at a concentration of 100 µM. Cells were subsequently lysed and subjected to 
immunoprecipitation as described above. The polyclonal antibody A7 was used for probing of 
wtPrP and PrP∆(23-90).  
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2.12   Fluorescence Activated Cell Sorting (FACS) analysis  
 
2.12.1  Cell surface analysis 
 
FACS buffer       2.5 % fetal calf serum (FCS) 
        0.05 % Na- Acide  
        in PBS 
 
Propidium Iodide       0,02 % FACS buffer 
 
EDTA        1 mM in PBS 
 
 
For measuring of the cell surface expression of transiently transfected PrP constructs, N2a 
cells were detached from culture dish with 4 ml 1 mM EDTA after reaching 70-80 % 
confluence . About 1x105 cells were transferred to FACS-Polystyrene round bottom tubes and 
pelleted by centrifugation at 1200 rpm for 5 min. Cells were resuspended in 500 µl FACS 
buffer and placed in ice for 5 min. The tubes were then centrifuged again for 2 min and cells 
were incubated with the primary antibody (3F4, 1:100 in FACS buffer) and placed on ice for 
45 min. Cells were washed with 1 ml FACS buffer and centrifuged for 2 min. The wash-step 
was repeated for 3 times. For detection of 3F4-bound proteins, cells were resuspended in 100 
µl buffer containing the Fluorescein-Isothiocyanate  (FITC)-conjugated  secondary antibody 
(goat anti mouse) and placed on ice for 30-45 min. cells were washed again  for 3 times. After 
the third wash 500µl propidium-jodide were added for staining of dead cells. Flow cytometry 
was then performed on a FACS (fluorescence activated cell sorter) Calibur (Becton and 
Dickinson) equipped with a 488 nm emitting argon laser. Forward and side scatters were 
collected as linear signals and all fluorescent emissions on a logarithmic scale. A gate based 
on FSC and SSC was set  to separate living and dead cells and ten thousand events were 
acquired inside the gate using Cell Quest software (Becton and Dickinson). 
Throughout the analysis, cells incubated only with the second antibody were used as a 
negative control and the resulting fluorescence signals subtracted from the values obtained 
using both antisera.  
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2.12.2  Intracellular analysis 
 
Saponin buffer      0.1 % Saponin in FACS buffer 
Ammonium-Chloride/Glycine   50 mM/ 20 mM 
Formalin (37 % formaldehyde)   10 %     
(Merck, Darmstadt)   
     
70-80 % confluent cells were detached from culture dish with 4 ml 1mM EDTA in PBS. 1-2 
ml of the suspension (100.000 cells) were transferred to FACS-Polystyrene round bottom 
tubes and pelleted by centrifugation at 1200 rpm for 5 min. Cells were resuspended in 200 µl 
10% formalin at room temperature for fixation. Tubes were then centrifuged for 2 min in 1.5 
ml PBS and the reaction was quenched with 200 µl ammonium-chloride/ glycine for 10 min 
at room temperature. Cells were washed once with 500 µl saponin buffer, resuspended in 
primary antibody (100 µl, concentration 1:100 in saponin buffer) and incubated on ice for 45 
min. Cells were washed with 1 ml saponin buffer and centrifuged for 2 min. The wash-step 
was repeated for 3 times, they were then resuspended in 100 µl buffer with the FITC-
conjugated secondary antibody and placed on ice for 30-45 min. Cells were washed again  for 
3 times and flow cytometry was performed as described above. 
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3  Results 
Detailed studies performed with the sulphated bis-hexasulphonated compound Suramin have 
revealed strong reduction of the detectable PrPSc level in prion infected cells and a significant 
delay of onset of the disease in peripherally inoculated mice, when the drug was applied at the 
time of infection (Gilch et al., 2001). The compound is known to down- regulate the cell 
surface expression of certain proteins and to interfere with their oligomerisation state (Stein et 
al., 1995). Suramin was seen to modulate the folding of PrPc inducing aggregation of fully 
matured molecules. Aggregates of misfolded full length PrPc were subjected to the quality 
control mechanisms of the cell and were transported directly from the trans-Golgi network 
(TGN) to late endocytic compartments for degradation therefore by-passing the site of PrPSc 
conversion. Further analysis evidenced an important role of the pre-octapeptide segment 
located in the N-terminal part of the protein (residues 23-50) in the modulation of these 
effects and in the activation of the quality control mechanisms for recognition of misfolded 
proteins (Gilch, Nunziante and Schätzl, personal communications). Other compounds have 
been seen to influence the trafficking of PrPc. Pentosan sulphate and related compounds 
dramatically reduced the amount of PrPSc by stimulating endocytosis thereby causing a 
redistribution of PrPc from the plasma membrane to late endosomes and lysosomes (Shyng et 
al., 1995). Since the N-terminal sequence of mammalian PrPc is rich in basic amino acids and 
each contain a consensus site for heparin binding (XXBXBX, where B is a basic amino acid 
and X another residue) (Cardin and Weintraub, 1989), the same sites have been hypothesised 
to mediate the binding to other sulphated compounds. The suggested function of PrPc as a 
chelator of extracellular ions or as a carrier for uptake and delivery of copper ions to 
intracellular targets (Pauly and Harris, 1998) has been linked to the binding sites for copper 
ions identified in the N-terminal histidine-rich octarepeats. In studies done with neuronal 
cells, a rapid endocytosis of PrPc upon exposure to physiologically relevant concentrations of 
Cu2+ or Zn2+ has been reported. Here, deletions of the octapeptide repeats or mutation of 
histidine residues in the central two repeats abolished endocytosis (Sumudhu et al., 2001). 
The natural trafficking of the cellular prion protein has been characterised to some extend. 
The molecule is localised on the cell surface within one hour after synthesis (Caughey et al., 
1989). The chicken PrPc, which shares a sequence identity of 33 % with the homologous 
mammalian protein, had been previously reported to constitutively cycle between the cell 
surface and endocytic compartments via clathrin coated pits (Shyng et al., 1993). The full 
length molecule was internalised with a T½ of 20 minutes and then returned to the cell surface 
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at a similar rate. Later reports however, evidenced that PrPc re-enters the cell via caveolae-like 
domains or cholesterol- and glycosphingolipid-rich rafts (Vey et al., 1996; Taraboulos et al., 
1995), where PrPc undergoes an initial proteolytic cleavage to produce an N-terminally 
truncated protein designated PrP-II (Haraguchi et al., 1989; Pan et al., 1992). 
The following work was carried out with the purpose to further characterise the transport 
kinetics of the cellular isoform of the prion protein along the secretory and endocytic pathway 
and to devise a function of the N-terminal amino acid sequence in this subcellular trafficking. 
 
3.1  Biochemical characterisation of PrPc constructs showing progressive N-terminal 
deletions 
For the determination of the relevance of the N-terminal part of the prion protein on its 
subcellular processing, several constructs, each of them characterised by a different deletion 
in its N-proximal amino acid sequence were designed and cloned by standard cloning 
methods (Fig. 7). The PCR technique was utilised to introduce restriction sites into distinct 
mouse PrP DNA sequences, which were amplified and cloned into the mammalian vector 
pcDNA3.1. Since neuroblastoma cell endogenously express wild type PrPc (wtPrPc), an 
epitope was introduced into the transfected constructs which is recognised by the murine 
monoclonal antibody 3F4. This epitope corresponds to the human and hamster sequence 109-
112 (when referred to the human sequence) and is not contained in the mouse PrP. All 
constructs were named referring to the human PrP sequence. 
 
PrP-WT GPI
ORPOR
PrP- (23-90)
GPI
del. 67 aa.
GPI
PrP- (68-91) del. 24 aa.
PrP- (23-51) 
GPI
del. 29 aa.
PrP- (48-93) GPI del. 44 aa.
∆
∆
∆
∆
 
Figure 7. Schematic representation of examined PrP constructs  
 
Wild type PrP and PrP deletion constructs used in this study were derived from murine PrPc, and all 
contain the 3F4 epitope (amino acides 109-112, vertical bars), which allows detection by the 
monoclonal antibody 3F4. Numeration refers to the human PrP sequence. Black and open bars 
represent signal peptide and GPI-anchor, respectively, hatched bars the octapeptide repeats (51-90), 
dotted bars amino acids  preceding the octapeptide region (23-50).  
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These constructs were then transiently transfected into the murine neuroblastoma cells N2a. 
All the experiments were carried out 72 hours after transfection, in order to allow significant 
expression of the constructs by the cells. Where necessary, the use of the antibody 3F4 
allowed discrimination between endogenous and transfected prion proteins. All experiments 
with the deletion constructs described in this study were performed in parallel with transfected 
wtPrPc, in order to rule out possible effects on the kinetics of the proteins due to 
overexpression or to metabolic stress upon the transfection. The deletion mutants were first 
characterised biochemically, and their properties compared to those of wtPrPc, in order to 
assess whether truncation of residues within the N-terminal segments affected their folding 
and glycosylation patterns. N2a cells transfected with wtPrPc or with the mutated proteins 
were lysed and then subjected to a solubility assay, which involves ultracentrifugation at 
100,000 g for 1 hour in the presence of N-lauryl sarcosine for separation of the soluble from 
the detergent-insoluble fraction. Immediately after centrifugation, the supernatant was divided 
into two equal fractions and one of them subjected to digestion with Proteinase K (PK). These 
two assays are often applied for separation or differentiation of PrPc (soluble in detergents and 
PK sensitive) from PrPSc (insoluble and partially PK-resistant). These features of PrPSc are 
related to its misfolded and aggregated conformation and can therefore give information about 
the folding of proteins, e.g. of the transfected constructs used in this study. The centrifuged 
pellets and the supernatants (+ and – PK) were then subjected to SDS-PAGE and analysed in 
a Western Blot, using the antibody 3F4. All were mainly detected in the soluble fraction and 
were found to be PK-sensitive, as was expected for wtPrPc (Fig. 8A). It was therefore 
concluded that truncations within their N-terminal amino acid sequence did not significantly 
affect the solubility and PK-resistance of these proteins and therefore their conformation. On 
a polyacrylamide gel, wtPrPc migrated with its characteristic glycosylation pattern: un-, 
mono-, and diglycosylated bands were detected at 25, 28 and 33 kDa, respectively (Fig. 8A, 
lane 2). To verify that the other constructs were also properly glycosylated, aliquots of the 
lysates were subjected to an N-glycosidase F (PNGase F) digestion (Fig. 8B). This 
glycosidase cleaves NH2-glycans from their protein attachment sites, a glycosylated protein 
therefore migrates, upon treatment, in its unglycosylated form on an SDS-PAGE gel. For all 
deletion constructs, only one single band, corresponding to the unglycosylated form, was 
detected upon digestion with PNGase F. These results confirmed the N-glycosylation of the 
analysed proteins.  
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Figure 8. Biochemical properties of wtPrPc and PrP deletion mutants 
(A) For comparison of the biochemical behaviour of the different mutants used in this study with that 
of wtPrPc, postnuclear lysates of N2a cells transiently transfected with wtPrPc or with the described 
PrP deletion constructs were divided into two aliquots. One was subjected to a solubility assay, the 
other one was treated with 20 µg/ml proteinase K (PK). The detergent- insoluble pellets (lanes 1, 4, 7, 
10, 13), the supernatants (lanes 2, 5, 8, 11, 14) and the PK-treated fractions (lanes 3, 6, 9, 12, 15) were 
all analysed by immunoblotting using the monoclonal antibody 3F4. All constructs were soluble in 
detergents and sensitive to PK treatment.  
(B) Fractions (200 µl) of postnuclear lysates described in (A) were treated overnight with PNGase F 
for deglycosylation of the proteins and then subjected to immunoblotting with the antibody 3F4. All 
proteins migrated as single, unglycosylated bands. Molecular size markers are shown in kDa on the 
left. 
 
 
 
3.2  Effect of  progressive N-terminal  deletion on the internalisation of murine PrPc 
The first step in the characterisation of the subcellular trafficking of the prion protein was the 
analysis of its endocytosis. For this purpose, internalisation of wtPrPc was first compared to 
that of three constructs presenting deletions of different length in their N-terminal part: 
PrP∆(23-51) lacked the 29 amino acids between the signal peptide and the octapeptide 
repeats, in PrP∆(48-93) a segment of 44 residues encompassing the octapeptides was deleted, 
and in PrP∆(23-90) the complete N-terminus (67 residues after the signal peptide, therefore 
comprising octapeptide repeats and the region preceding them) were missing. N2a cells 
transiently expressing these proteins were incubated on ice with PBS containing sulfo-NHS-
biotin (pulse). This small molecule is membrane-impermeable and only binds to free amino 
groups of proteins localised at the outer leaflet of the plasma membrane. The low temperature 
inhibited further transport of proteins to and from the cell surface, so that only a defined 
population was labelled. The cells were then either lysed immediately after the labelling or 
were placed into an incubator at 37 °C for the described time periods to allow internalisation 
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of the labelled proteins (chase). Subsequent treatment of the cells with trypsin on ice which 
digests surface-located proteins, allowed discrimination of proteins that had been internalised 
during the chase from those still localised at the plasma membrane. All cells were then lysed 
and the wtPrPc and the mutants were immunoprecipitated with the antibody 3F4. After SDS-
PAGE, biotin-conjugated PrPs were detected by incubation with streptavidin, which binds 
with high affinity to biotin. Since all constructs could be detected upon labelling with biotin 
immediately before the chase, it was deduced that they were all localised on the cell surface. 
(Fig. 9A, lanes 1, 8, 14 and 18). Additionally, specific PrP signals disappeared upon mild 
treatment with trypsin. This assay therefore confirmed that the deletions in the N-terminus did 
not prevent the transport to the cell surface along the secretory pathway. After biotinylation, 
the different glycosylation bands were more difficult to devise. To confirm whether this was 
due to interference with the biotin molecules or  to detection of unspecific signals, 
immunoprecipitation with N2a cells transfected with the unrelated plasmid pEGFP was 
performed using the antibody 3F4. In this case no signal could be detected, confirming that 
the bands monitored upon immunoprecipitation of the transfected PrPs were specific and 
represented the constructs. Analysis of the signals detected after trypsin treatment of wtPrPc 
and of PrP∆(23-51), the mutant missing the 29 amino acids preceding the octapeptide repeat 
sequence,  after 45 min of chase, revealed that only the wild type protein had been efficiently 
internalised (Fig. 9A, lanes 4 and 11). On the other hand, after 60 min both constructs had 
entered the cells, although in different amounts. The intensity of the visualised bands was 
quantified with an appropriate computer programme and the signals detected after trypsin 
treatment compared to those untreated at the same time point. This quantification of the blots 
revealed that ~72 % of wtPrPc had been endocytosed, whereas the amount of PrP∆(23-51) 
only measured ~32 % (Fig. 9B). In contrast, neither PrP∆(48-93), which lacked the 
octapeptide repeats, nor PrP∆(23-90) in which the longest segment had been eliminated, could 
be detected inside the cell after 60 min (Fig. 9A, lanes 17 and 21).  
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Figure 9. Comparison of internalisation kinetics of wtPrPc and deletion mutants after 45 and 60 
min of chase 
 
(A) N2a cells were transfected transiently with wtPrPc or PrP deletion mutants using Fugene 
transfection reagent. 72 h after transfection cells were surface-biotinylated on ice for 15 min and then 
incubated for 0, 45 or 60 min at 37 °C. They where lysed immediately (-) or treated with trypsin (+) 
for 10 min on ice before harvesting and were then immunoprecipitated with the antibody 3F4, in order 
to detect only the transfected proteins. Lane 7 depicts lysate from N2a cells transfected with the 
unrelated plasmid pEGFP and precipitated with the monoclonal antibody 3F4, as a control. The 
samples were subjected to SDS-PAGE and the signals were detected by 1 h incubation with 
peroxidase conjugated streptavidin. Molecular size markers are depicted on the left (kDa). The 
autoradiogram reveals a delayed internalisation for all analysed deletion constructs. 
(B) The signals from (A) were quantified and the amount of internalised protein after 45 and 60 min 
was calculated as a percentage of protein without treatment with trypsin (100 %) at the same time 
point (each bar represents mean values from two independent experiments). The blot was digitised 
using  an APB-Image Scanner and specific bands quantified with Master-1d analysis software. 
 
In order to evaluate kinetics of internalisation for PrP∆(48-93) and PrP∆(23-90) in more 
detail, an analogous biotinylation assay with prolonged chase times was performed with these 
two constructs (Fig. 10). This experiment confirmed extremely impaired endocytosis for both 
proteins: after 3 and 6 h of chase almost no specific signals were detected within the cell (Fig. 
10A, lanes 4, 6, 12 and 14). Quantitative evaluation of the blot revealed that the amount of 
PrP(48-93) molecules located intracellularly after 10 h was 65 % of the total amount of 
protein rescued at the same time point without treatment with trypsin (Fig. 10A, lane 15 and 
16 and Fig. 10B). On the contrary, the levels of intracellular PrP∆(23-90) remained extremely 
low throughout the chase (lanes 4, 6 and 8) and only reached ~7 % of the total amount of PrP 
after 10 h. Taken together, these two assays evidenced altered kinetics of endocytosis for all 
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PrP constructs analysed, longer deletions in the protein sequence caused  stronger impairment. 
These results therefore argue for a correlation between the length of the N-terminal truncation 
and the efficacy of PrP internalisation. 
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Figure 10. Internalisation kinetics of  PrP∆(23-90) and PrP∆(48-93)  
 
(A) Transiently transfected N2a cells expressing PrP deletion mutants were surface biotinylated  on ice 
and then incubated at 37 °C for 0, 3, 6 and 10 h, respectively. Cells were harvested directly or treated 
with trypsin for 10 min on ice and then lysed. PrPs were immunoprecipitated with the monoclonal 
antibody 3F4. The blot shows samples treated (+) and untreated (-) with trypsin. The bold numbers on 
top indicate chase times (in hours) after the pulse. Molecular weight markers are indicated in kDa on 
the left. The construct with the longest deletion showed a more impaired endocytosis and was mainly 
localised on the cell surface even after 10 h of chase. 
(B) Mean values from two independent experiments represent the amount of internalised protein 
expressed as a percentage of the total labelled protein without trypsin digestion (at the same time 
point) and plotted as a function of different time points. 
 
3.3  Equal detection of wtPrPc and PrP∆(23-90) in the culture medium 
The partial or complete removal of the N-terminal part of the prion protein prolonged the 
presence of the protein on the plasma membrane. Particularly for PrP∆(23-90), the amount of 
protein which could be detected intracellularly, even after a long chase, was extremely low. A 
small quantity of PrPc has been reported to be released from cultured cells and to be shed into 
the medium (Borchelt et al., 1990; Caughey et al., 1989; Parizek et al., 2001), and a soluble 
N-terminally truncated PrP was seen to be released from human platelets (Perini et al., 1996). 
To test whether inefficient endocytosis of the PrP deletion constructs results in a more 
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pronounced shedding into the culture medium as means to avoid accumulation, a pulse chase 
experiment was carried out. N2a cells transiently expressing wtPrPc or PrP∆(23-90) were 
metabolically labelled with [35S]-methionine/cysteine for 1 h and then chased for 1 or 6 h at 
37 °C. The transfected proteins were subsequently recovered from the cells after lysis or from 
the culture medium, upon immunoprecipitation with the antibody 3F4. All samples were 
subjected to PNGase F treatment for deglycosylation of the proteins in order to facilitate 
comparison of the signals and were run on an SDS gel. Upon deglycosylation, single bands 
were detected in the lysates at 25 kDa for wtPrPc and at 19 kDa for the truncated PrP (Fig. 
11). The levels monitored for both proteins in the medium after 6 h were comparable (Fig. 11, 
lanes 4 and 8), the slightly reduced amount of PrP∆(23-90) in the lysates and in the medium 
probably due to the lower efficiency of transfection (when comparing lysates of the two 
constructs). Increased shedding of PrP∆(23-90) could therefore be excluded. 
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N2a cells transiently expressing wtPrP  
or PrP (23-90) were metabolically
labeled for 1 and then incubated 
for 1 or 6 h at 37 °C  before lysis. The cells 
(L) and the corresponding culture medium 
(M) were then immunoprecipitated with
the antibody 3F4. All samples were 
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PNGase F and run on an SDS-PAGE gel. 
No increased release of PrP (23-90) was
de tec t ed in  t he  cu l tu re  med ium.
c
∆
∆
Figure 11. Detection of wtPrP  and PrP (23-90)
in the culture medium
c ∆
 
 
 
3.4  Lysosomal accumulation of PrP∆(23-90) upon treatment of the cells with leupeptin 
Since no increase in the level of medium-recovered PrP∆(23-90) had been registered, and 
only low amounts of this protein could be detected within the cell upon biotinylation, more 
information about the degradation route of this protein was collected with another pulse-chase 
experiment. Wild type PrP is normally internalised from the plasma membrane and 
transported along the endocytic pathway to late endosomes and lysosomes where the final 
degradation occurs. In the present assay, N2a cells were thus treated with the endosomal and 
lysosomal protease inhibitor leupeptin, which covalently binds to serine and thiol proteases, 
inhibiting their activity and the degradation of proteins in the lysosome. After 
immunoprecipitation of the transfectd proteins with the antibody 3F4 and PNGase F 
deglycosylation, specific bands for wtPrPc and PrP∆(23-90) were monitored (Fig. 12). For 
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both proteins the signals became stronger when the cells had been treated with leupeptin, 
implying that they follow the lysosomal pathway for degradation (Fig 12, lanes 2 and 4). In 
spite of the slower rate of endocytosis monitored in the earlier experiments, accumulation of 
PrP∆(23-90) in the lysosomes upon inhibition of proteasomal activity, showed that the cells 
were still able to internalise this construct and to direct it to acidic compartments for final 
degradation. Whether the pathway used for endocytosis is the same as for wtPrPc or whether 
an alternative one is adopted, still needs to be elucidated.  
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3.5  Effect of N-terminal deletion on the half-life of PrPc 
The experiments described above evidenced prolonged permanence of PrP deletion mutants 
on the cell surface and localisation in the same compartments of degradation evidenced for 
the wild type. The following assay was therefore aimed at a more detailed characterisation of 
the kinetic of degradation and stability of  the truncated PrPs. In a pulse-chase experiment the 
half-lives of wtPrP, PrP∆(23-90) and PrP∆(48-93) were compared. N2a cells expressing these 
constructs were metabolically labelled with [35S]-methionine/cysteine for 1 h and either 
directly harvested or chased for the indicated intervals of time in [35S]-free culture medium 
before lysis. PrP present in the lysates was immunopurified with the polyclonal anti-PrP 
antibody A7, deglycosylated with PNGase F, and the decrease in the intensity of the signals in 
time was analysed by SDS-PAGE (Fig. 13A). The gel was evaluated by densitometric 
analysis and the specific signals quantified as fractions of the signal observed immediately 
after the pulse period (Fig. 13B). This analysis revealed a half life for newly synthesised 
wtPrPc of 2.6 h. This turnover was comparable, although slightly slower than the one 
measured in other studies done with untransfected cells (Borchelt et al., 1990). In contrast, the 
turnover of the deleted PrP molecules proved to be significantly prolonged. Quantification for 
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PrP∆(48-93) and PrP∆(23-90) indicated a half-life of ~4.2 and ~4.8 h, respectively. Both 
values were almost twice as long as those registered for wtPrPc. As the antiserum used in this 
assay was the polyclonal antibody A7, which recognises both endogenous and transfected 
PrP, also the full length PrPc was precipitated from the lysates of cells expressing the 
truncated proteins and could be monitored on the blot as a single band of 25 kDa. This 
phenomenon underlines the difference in the turnovers of the constructs. These data 
corroborate the model that prolonged localisation of PrP costructs on the plasma membrane 
due to N-terminal deletion also affects the degradation of these proteins. 
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Figure 13. Deletion of the N-terminus prolongs turnover of PrPc  
 
(A) Confluent N2a cells transiently expressing wtPrPc, PrP∆(23-90) or PrP∆(48-93) were 
metabolically labelled with [35S]-Met/Cys for 1 h at 37 °C and were either lysed immediately after the 
pulse or incubated in culture medium without [35S] at 37 °C for 2, 3, 6, 8 and 22 h before harvesting. 
Proteins were precipitated with the ployclonal antibody A7 and deglycosylated  with PNGase F to 
facilitate molecular size comparison and quantification. Samples were subjected to SDS-PAGE and 
autoradiography. Molecular size markers are designated in kDa on the left. Bars on the right indicate 
unglycosylated  PrP-specific bands belonging to each construct. The autoradiogram evidences that the 
PrP deletion constructs are degraded with a slower kinetic, compared to that of wtPrP. 
(B) Evaluation of autoradiograms from three independent experiments performed as described in (A), 
to determine the half-life of the different PrPs. The amounts of protein are expressed as percentage of 
total protein rescued directly after the labelling period and are plotted as a function of the chase time 
points. The data points were fitted to an exponential curve using non-linear regression analysis.  
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3.6  Modulation of the transport through the secretory pathway by the N-terminal 
segment of the prion protein  
Since the data collected so far had shown that the N-terminal part of PrPc modulates  
endocytosis and stability of the protein, the transport of the prion protein and of the different 
deletion constructs through the secretory pathway was examined, to identify a possible 
function of the N-proximal segment also in this arm of the PrP life-cycle. Pulse-chase 
experiments coupled with trypsin digestion were used to evaluate the time required by wtPrPc 
and PrP deletion constructs to reach the plasma membrane. After transfection, a metabolic 
pulse of  5 min allowed the labelling of a more homogenous protein population shortly after 
translation and translocation into the ER. Cells were then harvested immediately or chased for 
the indicated time periods to allow transport to the cell surface. Molecules that had reached 
the plasma membrane were separated from those still undergoing synthesis or transport to the 
cell surface by mild trypsin treatment on ice for 10 min and were then immunoprecipitated 
with an anti-PrP antibody. All samples were deglycosylated with PNGase F for simplifying 
quantitative comparison of the constructs. Immediately after the pulse, wtPrPc and the PrP 
constructs were still protected from extracellular trypsin digestion (Fig. 14, lanes 2, 8 and 14), 
consistent with their localisation in the endoplasmic reticulum and/or Golgi apparatus. A 
relevant decrease in the wtPrPc signal was monitored after 60 min of chase (Fig. 14A, lane 4), 
and confirmed that most of the wtPrPc molecules reach the cell surface within 1 h after 
synthesis. This value was consistent with those reported earlier by other groups (Caughey et 
al., 1989; Borchelt et al., 1992). For the other two constructs analysed here, even after 60 min 
of chase, considerable amounts were still detectable intracellularly  (Fig. 14A, lane 10 and 
16). Of note,  PrP∆(48-93) was still clearly detectable after 75 min of chase. Phosphor-
Imaging analysis evidenced that, whereas after 45 min 50 % of total wtPrPc could still be 
detected after trypsin treatment, this level rapidly decreased to ~25 % after 60 min. 
Quantification of the signals for PrP∆(23-90) and PrP∆(48-93) revealed that 50% of the 
labelled proteins were not susceptible to trypsin treatment after 65 and 75 min, respectively. 
These repeated and reproducible findings corroborated the notion that deletions within the N-
terminal sequence negatively affect the transport of PrPc also along the secretory pathway. 
The sorting of PrP∆(48-93) to the cell surface seemed to be more delayed than that of 
PrP∆(23-90), possibly due to a particular conformation of the construct. 
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Figure 14. Kinetics of transport of wtPrPc, PrP∆(23-90) and PrP∆(48-93) to the cell surface 
 
(A) wtPrPc and N-terminally truncated constructs were transiently transfected into N2a cells. They 
were then metabolically labelled with [35S]-Met/Cys for 5 min on ice and chased at 37 °C in [35S]-free 
culture medium for 0, 45, 60, 75, 90 min, respectively. For each construct, one plate was harvested 
immediately after the pulse or treated with trypsin for 10 min on ice and lysed. All other plates  were 
subjected to digestion with trypsin after the chase. Proteins were immunoprecipitated with antibody 
A7, deglycosylated with PNGase F and subjected to SDS-PAGE. The autoradiogram shows PrP 
signals before (-) and after (+) treatment with trypsin. Molecular size markers in kDa are shown on the 
left. Deletion of the N-terminus results in a delayed transport along the secretory pathway. 
(B) Phosphor-Imager evaluation of autoradiograms representing amount of proteins detected after 
digestion with trypsin. Each point represents a mean value of three independent experiments. 
Quantities  are calculated as a percentage of  protein precipitated immediately after the pulse without  
trypsin-treatment. 
 
For further analysis of the domains involved in the trafficking of PrPc, the transport of 
PrP∆(23-51) and that of another construct in which three of the five octapeptide repeats had 
been removed (residues 68-91), were compared. Also in this analysis, a pulse-chase assay 
combined with trypsin treatment of transfected cells, using the same time points for easier 
comparison was used (Fig. 15A and B). In these two constructs, segments of similar length  
were deleted in distinct sections of the N-terminus. If different kinetics of transport were 
measured, these should therefore reveal the presence of a more limited domain with a 
dominant sorting role in the secretory pathway. The time for detection of 50 % of intracellular 
PrP was 65 and 70 min for PrP∆(68-91) and PrP∆(23-51), respectively, which was longer 
than that measured for wtPrPc (45 min). The bands detected in this assay migrated as doublets 
under these conditions, rather due to incomplete deglycosylation than to the presence of 
 55
 Results 
__________________________________________________________________________________________ 
degraded forms of the proteins, since they were already present immediately after the pulse. 
From these results two conclusions can be drawn: truncation of even a reduced segment 
within the N-terminus negatively interferes with the efficiency of transport of PrPc to the 
plasma membrane. More important, no specific domain within the stretch of the PrP analysed 
in this study displays a dominant role, since deletions encompassing or preceding the 
octapeptide repeat region similarly affect this pathway. 
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Figure 15. Kinetics of PrP∆(68-91) and PrP∆(23-51) transport through the secetory pathway 
monitored by pulse-chase experiments 
 
(A) PrP deletion constructs were transfected into N2a cells and metabolically labelled with [35S]-
Met/Cys for 5 min. For both constructs one plate was lysed immediately after the pulse or treated with 
trypsin, the others were incubated for 45, 60, 75 and 90 min at 37 °C and then treated with trypsin for 
10 min on ice before harvesting. Proteins were immunoprecipitated with the antibody A7, 
deglycosylated with PNGase F and subjected to SDS-PAGE. Bars on the right indicate PrP specific 
signals. Both constructs migrated as doublets, under these conditions. On the left molecular size 
markers are shown in kDa. Small deletions in different parts of the N-terminus can impair transport of 
PrP molecules to the cell surface. 
(B) The diagrams show the amount of protein detected at each time point after treatment with trypsin. 
Signals from two autoradiograms were quantified by Phosphor-Imager analysis and depicted as 
percentage of protein precipitated immediately after the pulse without trypsin treatment. 
 
3.7  N-terminal deletions and PrP glycosylation  
The experiments described above have evidenced a general delay in the transport of PrPc to 
the cell surface when segments within the N-terminal part were deleted. A more accurate  
characterisation of this impaired pathway was therefore necessary. In a first attempt to 
identify a specific compartment or membranous vesicles involved in the secretory pathway, in 
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which N-terminal truncation of PrPc might result in a delayed transport to the cell surface, 
immunoprecipitated samples were subjected  to Endoglycosidase-H (Endo-H) treatment. This 
enzyme  hydrolyses high-mannose oligosaccharides linked to the proteins while these are in 
the ER or ER cis-Golgi intermediate compartment (ERGIC) preceding the medial Golgi stack. 
(Tarentino and Plummer, Jr., 1994). Once glycoproteins have reached the mid-Golgi 
compartment, removal of mannose residues by mannosidase I and II and addition of a single 
sugar residue by N-acetyl-glucosamine transferase generates a structure called “inner core” of 
the complex oligosaccharide, which is resistant to degradation with Endo-H (Fig 16). 
Treatment of proteins with Endo-H therefore enables characterisation of their glycosylation 
state and localisation.  
   
Inner core
Inner core Terminal region
ER mannosidase
Figure 16.  Processing of  glycans in the  Golgi .
High mannose glycans generated in the ER reach the Golgi 
where additional trimming and further additions are carried
out to form complex oligosaccharides. Modifications occur
in the fixed order illustrated in the figure. This process
generates a structure called inner core, consisting of
2  N- a ce ty l -g luc o sa m in e  an d  3  m a n n o se  r e s idu es .
At this point the oligosaccharide becomes resistant to degradation 
 
by the enzyme Endoglycosidase-H (Endo-H). Endo-H resistant 
glycans have already left the mid-Golgi compartment. Additions to
the inner core generate the terminal region. The residues that can
be added include N-acetyl-glucosamine, galactose, and sialic acid.
(F igur e  mod i f i ed  f ro m  B .Le win ,Ge nes  V II ,  2 000 )
 
In pulse-chase experiments, the time points at which wtPrPc, PrP∆(23-90) and PrP∆(48-93) 
acquired Endo-H resistance was measured (Fig. 17). Acquisition of Endo-H resistance at 
different time points for PrPc and PrP deletion constructs would localise the compartment of 
delay before the mid-Golgi stack. If all constructs became resistant at the same time, then the 
trans-Golgi or a vesicular compartment between trans-Golgi and plasma membrane would 
represent the compartment where this impairment takes place. After metabolic labelling of 
prion proteins for 5 min, these were either immediately harvested or chased for different time 
intervals before lysis. All samples were immunoprecipitated with the antibody 3F4 and 
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subjected to Endo-H treatment. The experiment was performed twice with different chase 
times. Treatment of wtPrPc with Endo-H immediately after labelling resulted in a shift of the 
33 and 28 kDa bands to a band of ~25 kDa (Fig. 17A, lane 2). Initial signs of resistance for 
wtPrPc were detected after 30 min of chase, when the mono-glycosylated form appeared (lane 
6) and became more prominent after 40 min (lane 8). Observing the other two constructs, we 
could detect the conversion to unglycosylated molecules of 19 and 22 kDa for PrP∆(23-90) 
and PrP∆(48-93), respectively, when treated with Endo-H immediately after the pulse (Fig. 
17A lane 12 and Fig. 17B lane 2). Partial resistance was detected after 40 min for both 
deletion  mutants (Fig. 17A lane16 and Fig. 17B lane 8).  
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Figure 17. Endo-H digestion of  wtPrPc, PrP∆(23-90) and PrP∆(48-93)  
 
Confluent N2a cells transfected with wtPrPc, PrP∆(23-90) or PrP∆(48-93) were metabolically labelled 
with [35S]-Met/Cys for 5 min on ice and then either immediately harvested or incubated in culture 
medium without [35S] at 37 °C for different chase periods before lysis. Proteins were then 
immunoprecipitated with antibody 3F4 and treated with (+) or without (-) Endo-H overnight at 37 °C 
before analysing by SDS-PAGE. Bars on the right indicate unglycosylated PrP specific bands. 
Molecular size markers are shown (in kDa) on the left. None of the three proteins analysed became 
completely Endo-H resistant after 40 min of chase. 
 
Since complete Endo-H resistance had not been monitored for any of the analysed constructs, 
the assay was repeated applying longer chase periods after the pulse (Fig. 18). Under these 
conditions,  the mono- and di-glycosylated bands of wtPrPc could be detected, after treatment 
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with Endo-H, between 40 and 50 min (Fig. 18A, lanes 4 and 6). Both the other deletion 
constructs became fully Endo-H resistant after 50 min (Fig. 18A, lane 16 and 18B, lane 6). As 
deletions within the N-terminal part of PrPc do not profoundly affect kinetics of glycosylation 
and transport of PrPc to the Golgi, delay in reaching the plasma membrane seems to take place 
in a compartment downstream of the mid-Golgi. 
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Figure 18. Endo-H digestion of  wtPrPc and PrP deletion constructs after 40-70 min chase 
periods 
 
Confluent N2a cells transiently  expressing wtPrPc, PrP∆(23-90) or PrP∆(48-93) were metabolically 
labelled and chased as described in the previous figure. Proteins were then immunoprecipitated with 
antibody 3F4 and treated with (+) or without (-) Endo-H previous to analysis by SDS-PAGE. Bars on 
the right indicate unglycosylated PrP specific bands. Molecular size markers are shown (in kDa) on 
the left. All PrPs analysed became completely Endo-H resistant between 40 and 50 min of chase. 
 
3.8  Biochemical characterisation of a chimeric prion protein 
In light of the results described above, further analysis of the influence of the N-terminal part 
on subcellular trafficking was undertaken by substituting the mouse N-terminus with that of a 
far remote species in one of the analysed constructs. An IMAGE clone containing the cDNA 
comprising 387 bp of the coding sequence of  the Xenopus laevis PrP was used for cloning of 
a chimeric protein. The 47 residues following the signal peptide represent the N-terminal end 
of the mature Xenopus PrPc (amino acids 23-69), and were therefore inserted into the 
truncated mouse PrP∆(23-90) with PCR cloning techniques. This segment, although showing 
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homology to the mouse PrP-N-terminus, especially in the basic N-proximal stretch, is 20 
amino acid shorter than that of  the mouse, mainly due to the lack of repeat structure (Fig.19).  
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Figure 19. Schematic representation of mouse and Xenopus laevis wtPrPc and of the chimeric 
construct Xen(23-69) 
 
(A)The proteins are depicted with their structural features and post-translational modifications. The 
polypeptide chains are divided into distinct segments according to the different biochemical 
properties. The numeration of amino acids refers to the human PrP sequence. The figure shows that for 
construction of Xen(23-69), residues 23-69 of the Xenopus PrP have been introduced into the mouse 
PrP∆(23-90), following residue 22. 
(B) Comparison of the X. laevis prion protein N-terminal amino acid seqence with the mouse. Grey 
boxes denote identical residues. 
 
The resulting protein Xen(23-69) was transiently expressed in N2a cells and was 
characterised biochemically in a solubility assay in the presence of N-lauryl sarcosine and 
upon PK-digestion, using the antibody 3F4. The construct appeared to be soluble and PK-
sensitive and thereby had the characteristics of a properly folded, non aggregated prion 
protein (Fig. 20, lanes 2 and 3). After deglycosylation with PNGase F, the construct migrated 
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as a single band of about 23 kDa,  consistent with its shorter amino acid sequence (Fig. 20, 
lane 4). Its biochemical properties did not differ relevantly from those of the murine PrPc. 
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The postnuclear lysates of N2a cells expressing the
chimeric construct Xen(23-69) were analysed in a
solubility assay or were subjected to treatment
with 20 µg/ml PK for 30 min at 37 °C. One aliquot 
was used for PNGase F digestion. The resulting
fractions were examined in a Western Blot
developed with the antibody 3F4. Lane 1 and 2:
detergent insoluble (P: pellet) or soluble
(S: supernatant) fractions upon ultracentrifugation;
lane 3: lysate fraction treated with PK; lane 4:
aliquot treated with PNGase F for deglycosylation.
No specific signals were detected in the pellet
upon ultracentrifugation, nor after PK digestion.
PK
Figure 20. Biochemical characterisation
of Xen(23-69)
 
 
 
 
 
 
 
 The intracellular expression and the cell surface localisation of this protein were therefore 
analysed in a FACS analysis with a flow cytometry after immunofluorescence staining (Fig. 
21). Also in this case, the monoclonal antibody 3F4 was applied, in order to avoid a cross-
reaction with the endogenous PrPc. Both the chimeric and the wild type protein showed 
similar pattern of expression, indicating that the introduction of the Xenopus N-terminal 
segment into the mouse protein neither altered the expression levels nor prevented cell surface 
localisation of the chimeric protein. 
intracellular
surface
WT             Xen(23-69)
 
Figure 21. Similar levels of cellular expression for wtPrPc and Xen(23-69) 
 
The expression levels in N2a cells transiently transfected with wtPrPc or Xen(23-69) were measured 
by cytofluorometry 72 h post transfection. The upper panels show fluorescence histograms for the  
intracellular expression of the two proteins in permeabilised cells for one representative experiment. 
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X-axes represent the fluorescence intensity plotted against the number of cells (y-axes). In each 
experiment the expression in transfected cells (open diagram) was measured against that of 
untransfected ones (filled diagram). For each cell population 10,000 events were measured. The lower 
panel shows the cell surface expression in non-permeabilised cells. Living and dead cells were 
separated by staining with propidium iodide and gating. The histogram only shows the cells contained 
in this gate. In both assays the monoclonal antibody 3F4 was used for detection of the constructs. 
 
3.9  Restoration of the wild type phenotype by the Xenopus laevis N-terminus 
Once the biochemical properties and the correct surface expression of Xen(23-69) had been 
assessed, this protein was used to examine how the intracellular trafficking of the truncated 
mouse PrPc was affected by the N-terminal segment belonging to a phylogenetically remote 
species. The kinetic of endocytosis of this construct was analysed in a biotinylation assay 
followed by mild treatment of transfected N2a cells with trypsin, as described above. 
Immediately after the pulse, biotin labelled Xen(23-69) localised on the cell surface could be 
rescued upon immunoprecipitation with the antibody 3F4 (Fig. 22A, lane 1). Additionally, no 
signal was detected upon treatment of the cells with trypsin, confirming the presence of the 
protein at the outer leaflet of the plasma membrane (Fig. 22A, lane 2). Chase times of up to 
45 min at 37° C showed no signals upon trypsin treatment, only after 60 min specific bands 
could be detected (Fig. 22A, lane 6). This experiment showed that endocytosis of this 
chimeric protein occurred at a slower rate when compared to wtPrPc which was detected in 
the intracellular space after 45 min. Nevertheless, the introduction of an N-terminal sequence, 
although belonging to a remote species accelerated the internalisation of PrP∆(23-90). 
Quantification of the blot revealed an intracellular  level of protein of almost 60 % 1 h after 
the pulse. 
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Figure 22. Internalisation kinetics of Xen(23-69)  
 
(A) Transiently transfected N2a cells expressing chimeric PrP Xen(23-69) were incubated for 0, 45 or 
60 min at 37 °C, after surface biotinylation on ice for 15 min. Cells were lysed immediately (-) after 
the labelling, or were subjected to trypsin digestion (+) for 10 min on ice previous to lysis, and were 
then precipitated with antibody 3F4. Samples were subjected to SDS-PAGE and signals were detected 
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by streptavidin. Molecular size markers are depicted on the left (kDa). Xen(23-69) is efficiently 
internalised. 
(B) The bars represent the amount of PrPXen(23-69) internalised in the biotinylation assay depicted in 
(A), expressed as a percentage of total labelled protein without trypsin digestion (at the same chase 
time) and plotted as a function of different time points. 
 
A similarly interesting result was obtained in a pulse-chase analysis performed in order to 
follow the transport of Xen(23-69) through the secretory pathway. After a short metabolic 
pulse of 5 min, the protein was chased for up to 75 min as done previously with other 
constructs, deglycosylated with PNGase-F and then precipitated with the antibody A7 (Fig. 
23). Removal of surface localised proteins with trypsin revealed intracellular localisation of 
the chimeric construct until 45 min following the pulse; after 60 min of chase the signal 
became very faint (Fig. 23A, lanes 4 and 5). This kinetic of secretory transport for Xen(23-
69) mirrored those recorded for wtPrPc. Phosphor-Imager quantification revealed that 50% of 
Xen(23-69) moiety reached the cell surface after ~43 min (Fig 23B), a value very similar to 
that of wild type mouse prion protein. These data suggest that the N-terminus of Xenopus 
laevis, like the corresponding murine sequence, exerts the same intrinsic sorting functions and 
is able to restore the wild type trafficking kinetics. 
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Figure 23. Transport of Xen(23-69) through the secretory pathway to the cell surface 
 
(A) Xen(23-69) was transiently transfected into N2a cells, metabolically labelled with [35S]-Met/Cys 
for 5 min on ice and then chased in [35S]-free culture medium for 0, 45, 60, 75 min, respectively. One 
plate was harvested immediately after the pulse or treated with trypsin and then lysed. All other plates 
were subjected to treatment with trypsin on ice for 10 min before lysis. Proteins were 
immunoprecipitated with antibody 3F4, deglycosylated with PNGase F and subjected to SDS-PAGE. 
The blot shows PrP signals before (-) and after (+) treatment with trypsin. A molecular size marker in 
kDa is shown on the left. The transport of Xen(23-69) to the cell surface is not impaired. 
(B) Phosphor-Imager evaluation of the autoradiogram. The curve represents the amount of Xen(23-69) 
detected at each time point, after digestion with trypsin. Each point represents a mean value of two 
independent experiments. Quantities are calculated as a percentage of protein precipitated immediately 
after the pulse without  trypsin-treatment. 
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4  Discussion 
When the term prion was proposed by Prusiner in 1982, as the proteinaceous infectious 
particle responsible for numerous infectious neurodegenerative diseases in animals and 
humans, researchers were confronted for the first time with a pathogen which does not rely on 
nucleic acid for its own propagation. Huge steps toward the characterisation of the chemical 
properties and mode of transmission of the protease resistant PrPSc, of which prions mainly if 
not solely consist, have been made since then. It is nevertheless clear that full understanding 
of the mechanisms underlying these diseases also requires the knowledge of the function and 
the metabolism of the host encoded cellular PrPc, the protein undergoing profound 
conformational alteration and conversion into its pathogenic isoform. Despite the great body 
of knowledge obtained so far about structure and processing of the prion protein, several 
questions remain unanswered. Exceeding work has been done lately in order to characterise 
the still undefined function of this protein. The N-terminal part of the protein and its 
involvement in a cellular function have been a matter of intense study.  In both, the mainly α-
helical PrPc and the PrPSc, with its high β-sheet content, the N-terminus of the protein is 
devoid of a globular structure and remains protease sensitive after scrapie conversion (Riek et 
al., 1997; Donne et al., 1997; Liemann and Glockshuber, 1998; Prusiner, 1998). Still, during 
evolution, this segment of the prion protein has remained highly conserved, suggesting a 
defined pressure or a reason for this conservation. Following the work of other groups, the 
study presented here assesses a possible targeting function of the segment comprising residues 
23-90 of the mouse PrPc in the life cycle of this protein. 
 
4.1  N-terminal deletion does not affect the biochemical properties of the prion protein 
The constructs analysed in this study were based on the mouse PrP sequence and lacked 
segments of different length in their N-terminal end. The first experiments aimed at the 
characterisation of their biochemical properties. These were compared to those of the wild 
type prion protein in order to exclude that conformational changes or overexpression might 
influence the outcome of the subsequent analysis. The assays chosen for this purpose have 
often been used to differentiate between the pathogenic and the cellular isoform of the prion 
protein according to their different solubility in detergent and their sensitivity to treatment 
with PK. They have also been applied for characterisation of several PrP mutants expressed in 
cell culture or rescued from in vivo studies (Taraboulos et al., 1990a; Lehmann and Harris, 
1997). The insolubility and partial PK-resistance of PrPSc reflects its aggregated, 
conformationally altered state. When the deletion constructs were expressed in N2a cells and 
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were subjected to the mentioned assays, their behaviour did not differ from that of the wtPrPc. 
They all showed similar glycosylation patterns (un-, mono- and di-glycosylated form of the 
protein), although, according to their mobility on a polyacrylamide gel, some of the deletion 
mutants seemed to display glycans of higher molecular weight. Upon digestion with PNGase 
F, these proteins all migrated as a single unglycosylated band. The fact that in the following 
experiments membrane impermeable biotin could bind to them and that they could be cleaved 
from the cell surface by treatment with trypsin, confirmed that, at a steady state, these proteins 
were localised at the plasma membrane and showed similar levels of expression. Inside the 
cell, regulation of protein expression is ensured by quality control mechanisms operating at a 
the ER level and downstream  along the secretory pathway. These mechanisms apply to 
misfolded and as well as to incompletely  assembled proteins. The main strategies include 
retention in the ER, ER-associated degradation (ERAD) and retrieval to the ER from other 
organells. If proper maturation and folding with the assistance of ER-chaperones and folding 
enzymes fail, proteins are retranslocated to the cytosol and degraded by the proteasome. 
Truncations in the N-terminal polypeptide sequence of the PrP constructs did not seem to 
prevent correct folding in a way that would activate the quality control of the cell, as it was 
the case for other described PrP mutants (Rogers et al., 1990 ; DeArmond et al., 1997; 
Zanusso et al., 1999). Even a Golgi/TGN-based system for re-routing and lysosomal 
degradation of aberrantly folded proteins, described in yeast (Ellgaard et al., 1999) and 
recently proposed in an anti-prion study (Gilch et al., 2001), does not seem to apply to N-
terminally truncated prion proteins analysed in the present study. 
 
4.2  Progressive deletions within the N-terminus of PrPc result in reduced endocytosis 
Previous work done by other groups has characterised the endocytosis of the chicken PrPc 
(Shyng et al., 1993; Shyng et al., 1995b). Surface iodination and immunofluorescence 
microscopy have shown that this protein is rapidly internalised, with 40-50 % recovered 
inside the cell after 30 min of chase. This PrPc cycles between the cell surface and endocytic 
compartments where it is subjected to a proteolytic cleavage to yield a COOH-terminal 
fragment. These results are consistent with earlier investigations in cell culture extracts and 
partially purified fractions from the brain of Syrian hamsters which identified an N-terminally 
truncated molecule labelled PrPc-II representing a first degradation product of PrPc 
(Haraguchi et al., 1989; Pan et al., 1992). 
The analysis of the internalisation kinetics of mouse PrPc in the present work revealed that  
the endocytic pathway was impaired for all PrP deletion constructs when compared to wtPrPc 
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and that the degree of impairment correlated with the length of the deletion. About 3/4 of the 
total surface labelled wtPrPc entered the cell after 60 min of chase, whereas deletion of the 
pre-octapeptide segment negatively affected this pathway. The effect of the N-terminal 
truncation on the endocytosis of PrP was particularly evident when the internalisation of 
PrP∆(23-90) and PrP∆(48-93) was analysed: only after 10 h of chase 65 % of the total amount 
of surface labelled PrP∆(48-93) could be detected intracellularly. At the same time point, 
PrP∆(23-90) was still mainly localised on the cell surface. Interestingly, the glycosylation 
patterns monitored for the biotinylated contructs differed slightly from those monitored in the 
Western blot. One explanation for this evidence could be that the relative amount of 
glycosylation appears to be dependent on the cellular localisation of PrPc (Vorberg and Priola, 
2002) and the labelled population localised at the plasma membrane could therefore present 
different glycan ratios and profiles than the total PrPc population monitored in a Western blot 
analysis. Of note, unglycosylated PrP, which was rarely detected upon biotin labelling in the 
present study, was reported to be transported with slower kinetics to the plasma membrane 
(Taraboulos et al., 1992; Borchelt et al., 1990). The biotinylation studies reported here 
support the work done on chicken PrPc, although mouse PrPc seems to have slower 
internalisation kinetics. These differences might be explained by relatively poor homology 
between mammalian and avian PrP (~30 %) and by the longer N-terminus of chicken PrP 
which contains 8 hexapeptide repeats (Harris et al., 1991). The C-terminal fragment (20 kDa) 
described for chicken PrP upon proteolytic cleavage of the wild type protein in the endocytic 
compartments could not be detected in the biotinylation assays, either due to the slow rate at 
which this fragment is produced (~ 1 %/ h) or due to the slower kinetics monitored for mouse 
PrP. The endocytosis of murine PrP has also been analysed in other studies (Sumudhu et al., 
2001). The binding of copper to the histidine residues contained within the octapeptide 
repeats of PrPc has been seen to affect the cell surface localisation of the protein by 
stimulating endocytosis (Pauly and Harris, 1998; Marella et al., 2002). In these studies, 
deletions or mutations within the octapeptides abolished endocytosis. The assays presented 
here indicate that the octapeptide repeats are not the only element in the PrP sequence with an 
internalisation-promoting function, since considerable differences between the internalisation 
kinetics of PrP∆(23-90) and PrP∆(48-93) could be detected. The analysis of the endocytosis 
of PrP∆(23-51) supported this hypothesis. This construct presenting deletion of the residues 
preceding the octapeptide repeats also showed impairment in its endocytosis, although not as 
strong as for PrP∆(23-90). This would not be expected if only the octarepeat segment had a 
role in promoting internalisation.  
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The systems involved in importing proteins into the cell lead to several pathways in which 
proteins follow different routes. Transmembrane receptors that localise at the plasma 
membrane slide laterally into invaginations called coated pits surrounded by the 180 kDa 
protein clathrin for endocytosis (49-51 rev). These vesicles are released into the cytoplasm to 
form endocytic vesicles which transport their content toward the interior of the cell and fuse 
with the membrane of target compartments such as early endosome. The common mechanism 
in this process requires a relatively short sequence motif in the cytoplamic tail of the 
transmembrane proteins which is recognised by the multimeric adaptor protein complex AP-
2, (Bonifacino and Dell'Angelica, 1999; Matter, 2000),  leading to protein-protein interaction 
followed by internalisation. These domains are often characterised by the presence of a 
tyrosine residue to form a signal of the type YXXφ (where X represents Tyrosin, XX other 
amino acids and φ a residue with a bulky hydrophobic side chain), or NPXY (Asn-Pro-X and 
Tyr) located close to the C-terminus. In proteins that are internalised in response to ligand 
binding, the internalisation signal may be generated by a change in the conformation as a 
result of the binding. The lack of cytoplasmic domains in GPI-anchored proteins requires 
different mechanisms for their internalisation than those described above. PrPc, like most GPI-
anchored proteins (Parton et al., 1994; Skretting et al., 1999; Nichols et al., 2001), seems to 
be endocytosed via a clathrin-independent pathway, by associating with the 
glycosphingolipid- and cholesterol-rich raft membranes (Taraboulos et al., 1995; Vey et al., 
1996). Functionally different GPI-proteins have been shown to cluster within sphingolipid 
rafts at different densities and on different domains on the plasma membrane of the same cell 
(Madore et al., 1999). While, for example, the small adhesion molecule Thy-1 occupies a 
highly insoluble, fully ordered domain, rafts where PrPc is clustered appear to form a marginal 
boundary of semi-ordered lipids flanking the glycerolipid domain in which transmembrane 
proteins are embedded. Several transmembrane receptors have been shown to have GPI 
proteins as ligand binding subunits or to bind to GPI-anchored proteins and to translocate 
between different plasma membrane domains (e.g. the receptor for ciliary neurotrophic factor) 
(Davis and Yancopoulos, 1993). As described for the urokinase-type plasminogen activator 
(uPA) receptor (Nykjaer et al., 1992), clustering of PrPc in an intermediate semi-ordered lipid 
domain could promote binding to an endocytosing transmembrane factor. The data shown in 
the present work support a similar model in which the N-terminal half of PrPc binds, either 
directly or indirectly, to the extracellular part of a transmembrane protein containing 
internalisation motifs. The N-terminal segment of PrPc (or multiple regions within it) can 
represent the element responsible for this binding. The impairment in endocytosis seen for the 
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deletion constructs could therefore be explained by a reduced ability of these PrPs to bind to a 
putative receptor due to deletions within the binding epitope. It can not be ruled out that other 
elements in the polypeptide chain of PrPc might also play a role in this process. 
Recently, cell-binding and internalisation assays done by other groups have shown that the 
37-kDa laminin receptor precursor (LRP) and its mature form, the 67-kDa laminin receptor 
(LR), localise with PrPc on the cell surface and promote endocytosis of PrP (Gauczynski et 
al., 2001). It was therefore concluded that these molecules act as main cell surface receptors 
for PrP. As one of the two identified LRP-binding domains in the PrP sequence was mapped 
between amino acid 53 and 93 (Hundt et al., 2001), the 37-kDa/67-kDa laminin receptor 
might be involved in the impaired trafficking of PrPc described here. 
 
4.3  The N-terminal truncated form of the prion protein is not exceedingly released into 
the culture medium and accumulates in lysosomes upon protease inhibition 
The prolonged presence of PrP∆(23-90) at the outer leaflet of the plasma membrane identified 
in long chase period experiments led to first steps toward the characterisation of the fate of 
this protein. Several GPI proteins are shed from the cell membrane and exist as soluble 
proteins (Mizukami et al., 1995; Smith et al., 1997). Detectable levels (10-30 %) of PrPc have 
been found in the medium of cultured  neuroblastoma cells following chases of 4 and 16 
hours (Caughey et al., 1989). Recent work done with primary splenocytes monitored high 
amount of soluble PrPc shed into the medium (Parizek et al., 2001), probably due to the 
presence of phopspholipases contained in the culture medium, similarly to other GPI proteins 
(Lehto and Sharom, 1998). The levels of wtPrPc and PrP∆(23-90) rescued in the medium of 
the transfected cells in the described assay were comparable, there was no indication of an 
increased amount of N-terminal deleted protein shed by the neuroblastoma cells. The 
molecular weights of the proteins recovered in the serum and deglycosylated did not differ 
form those detected on the cell surface or intracellularly in other experiments, which leads to 
the assumption that phospholipases which might cleave the GPI-anchor from PrPc do not play 
a major role in this shedding process. As the level of actively released or catabolised PrP∆(23-
90) is not enhanced, it was concluded that this protein is eventually internalised by the cell, 
possibly via different mechanisms than those described for the wild type protein. Inhibition of 
lysosomal and endosomal proteases with Leupeptin showed that the deletion of the N-
terminal part of PrP did not prevent lysosomal localisation of this protein. Replacement of the 
GPI addition signal of PrPc with the transmembrane and cytoplamic regions of mouse CD4 
(Taraboulos et al., 1995) or with other C-terminal transmembrane domains (Kaneko et al., 
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1997a) targeted the protein to clathrin coated pits instead of cholesterol-rich membrane 
domains for internalisation. A re-routing of PrPc by the deletion of its N-terminal domain 
might be possible. Regardless of the pathway leading to endocytosis, this protein eventually 
reaches these acidic compartments for degradation. Additional degradation pathways for a 
subpopulation of this protein can not be ruled out and have to be assessed by use of specific 
inhibitors in the future. 
 
4.4  Deletion of the N-terminal part significantly affects PrPc turnover  
The reduced efficiency in endocytosis of PrP molecules with extended deletions in their N-
terminal sequence of their peptide chain allowed the assumption that these deletions might 
influence the turnover of these proteins. This hypothesis was confirmed in pulse-chase 
experiments which revealed a much longer half-life for the constructs with more pronounced 
truncations when compared to the wtPrPc. The half-life monitored for wtPrPc in this assay was 
2.6 h. This value was similar to that recently reported for PrPc degradation in primary cell 
cultures derived from lymphoid and nervous tissues (Parizek et al., 2001) and in 
neuroblastoma cells (Gilch et al., 2001), although it is slightly shorter than that reported in 
studies done by other groups on endogenous PrPc with scrapie infected and uninfected 
neuroblastoma cells (Caughey et al., 1989; Borchelt et al., 1990). On the other hand, the 
values registered for the two deletion constructs analysed in this study, the half-life was 
almost twice as long as for the wild type. These values correlate with the rate of endocytosis 
described earlier but they could also stand for a different pathway of internalisation. So far, it 
is not known whether raft specific proteases participate in PrPc degradation. Several GPI-
anchored peptidases have been described (Deddish et al., 1990; Hooper et al., 1990). 
Additional putative PrPc cleaving enzymes could also be present at the cell surface. A shift in 
the plasma membrane localisation of the construct analysed here could lead to decreased 
affinity or accessibility to the polypeptide chain and therefore result in prolonged turnover of 
the deletion proteins observed in this study. The analysis of murine homologues of mutations 
in the PrP gene associated with human prion diseases showed that these mutations can affect 
their biochemical properties and intracellular trafficking (Lehmann and Harris, 1996), but 
prolonged half-lives were not described. Of note, the constructs described in the present work 
did not display any evident alteration of their biochemical properties but nevertheless showed 
a distinctive subcellular trafficking. Interestingly, several compounds which strongly inhibited 
PrPSc formation by enhancing the rate of PrPc endocytosis, did not affect the turnover of PrPc, 
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although they shifted the distribution of this protein from the cell surface to an intracellular 
location (Shyng et al., 1995a). 
 
4.5  The N-terminus of PrPc and the secretory pathway 
The sorting of proteins to the cells surface along the secretory pathway is not a simple default 
process, since specific signals, closely related to those used for internalisation, are required 
for the inclusion of cargo into secretory vesicles and for its transport to the plasma membrane. 
The evidence obtained in the above mentioned assays for a modulating role of the N-terminal 
part of the prion protein in the endocytic pathway which also interferes with its degradation, 
led to the question of whether these effects are symptomatic of a more general function of this 
amino acid segment as a sorting determinant. The assay performed in the present work in 
order to characterise the transport of wtPrPc and the deletion constructs evidenced that the 
majority of  the wild type molecules reached the cell surface within 1 h after the pulse. These 
values are in line with those reported by other groups (Caughey et al., 1989; Borchelt et al., 
1990). Conversely, the transport of all the constructs lacking more or less extended portions 
of the N-terminal part occurred with lower efficiency. Although the impairment monitored 
here was not as pronounced as for the endocytic pathway, the kinetics of the two constructs 
presenting the longest deletions were characterised by a delay of almost 50 % compared to the 
wild type protein. These results also evidenced that even relatively small deletions can 
considerably impair the trafficking of the PrPc through the secretory pathway, as seen for 
PrP∆(23-51) and PrP∆(68-91). Of note, the different impact with which the N-terminal 
deletions affect the two pathways in the life cycle of the PrPc analysed, argue for the 
specificity of these results.  
The first attempt toward the characterisation of this impaired pathway in more detail was the 
Endo-H digestion of PrPs on the way to the plasma membrane. The aim was to localise a 
specific cellular compartment or vesicle in which the transport of the truncated proteins was 
hindered, which can be seen by the sensitivity of proteins to this enzyme depending on their 
localisation. This analysis revealed that, although first signs of complex oligosaccharides in 
the form of an Endo-H resistant monoglycosylated protein were detected at slightly different 
times (30 min for wtPrPc and 40 min for PrP∆(23-90) and PrP∆(48-93)), complete resistance 
of the fully glycosylated proteins was achieved for all constructs after ~50 min. These 
experiments also evidenced that immediately after 5 min of metabolic labelling wtPrPc as well 
as the deletion mutants were glycosylated. Since Endo-H hydrolysis of N-linked high 
mannose oligosaccharides attached to glycoproteins only occurs in the ER and cis/mid-Golgi, 
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the kinetics monitored here argue for the trans-Golgi or a post-trans-Golgi compartment as a 
probable site where the impairment in the transport to the cell occurs. A delay in the transport 
at an ER- or ER-Golgi intermediate compartment would result in retention in or retrieval to 
the ER from downstream organelles and in proteasomal degradation. Since all proteins are 
expressed on the cell surface, this is therefore less likely. 
This finding is in line with several studies about the biogenesis of epithelial cell surface 
polarity. In polarised cells, where the plasma membrane comprises functionally distinct 
domains differing in protein and lipid composition  (Simons and van Meer, 1988; Rodriguez-
Boulan and Powell, 1992; Craig and Banker, 1994) , the development and maintenance of this 
polarised distribution is achieved by the sorting of protein and lipid cargo via different 
trafficking routes from the TGN  (Winckler and Mellman, 1999; Mostov et al., 2000). It is in 
the lumen of the TGN that glycosphingolipids and cholesterol associate into clusters linked 
together by hydrogen bonds involving the sugar head groups in the exoplasmic leaflet and 
acyl chains to form lipid rafts. Cholesterol molecules function as spacers in the cytoplasmic 
leaflet between associating sphingolipids. These microdomains represent the carriers for 
delivery of proteins to the cell surface via the apical route. Vesicular integral membrane 
proteins (VIPs) associate to these sorting platform as stabilisers or as linkers to other proteins 
in the rafts (Fiedler et al., 1994). In this pathway, carriers move along microtubules to the 
apical surface (Lafont et al., 1999). After having crossed the subcortical network of actin 
cytoskeleton (Ojakian and Schwimmer, 1988; Fath and Burgess, 1993), the apical carriers 
dock and fuse with the cell surface by a mechanism involving the ubiquitous SNARE (soluble 
N-ethyl maleimide-sensitive receptor). As mentioned above, several specific protein 
determinants are required for incorporation of proteins into rafts and correct basolateral or 
apical transport. These are based on protein-protein (Mellman, 1996) or protein-lipid affinities 
via sequences in their polypeptide chains (Eaton and Simons, 1995; Simons and Ikonen, 
1997). Lipid attachment (e.g. palmitoylation) and N-glycans for secretory and membrane 
proteins can also serve as a targeting signal in cooperative protein-lipid affinities (Scheiffele 
et al., 1995; Zhao et al., 2000). The GPI anchor has been recognised as an important targeting 
domain for inclusion of proteins into rafts and correct delivery to the cell surface in different 
polarised epithelial cell types (Lisanti et al., 1989; Brown et al., 1989), beside acting as a 
sorting motif for exit from the ER (Muniz and Riezman, 2000). It was also seen to act in the 
sorting of PrPc: the substitution of the lipid anchor with a transmembrane domain redirected 
the prion protein to clathrin coated pits and prevented conversion into PrPSc (Taraboulos et 
al., 1995, Kaneko et al., 1997a). More recent studies have evidenced a slower transport of 
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PrPc trough the secretory pathway when the GPI- addition signal is missing and argue for 
glycosylation and membrane anchorage as co-operative processes (Walmsley et al., 2001). 
The studies reported here suggest that also the N-terminal part of PrPc is involved in 
subcellular trafficking and therefore represents one of the targeting signals for effective 
transport of PrPc both through the secretory pathway and for endocytosis. The deletion 
constructs analysed in this study do not seem to activate the ER- or post-ER-based cellular 
quality control mechanisms and therefore reach the plasma membrane. Nevertheless, the 
deletions might still influence the conformation of the protein which can explain the 
differences in the glycosylation patterns seen between the deletion mutants. This phenomenon 
would confirm the hypothesis raised by other groups, that the N-terminal region of PrPc might 
stabilise the conformation of the C-terminal domain of the molecule (Zulianello et al., 2000). 
Indeed this could also explain the slightly slower kinetics of the monoglycosylated form of 
the deletion mutants for acquisition of Endo-H resistance. Given the function of glycans in 
stabilisation and correct folding of proteins, the double glycosylation might compensate for a 
change in the conformation of the N-terminal deletion mutants, which would otherwise make 
the protein less capable of travelling through the secretory pathway (as seen for the 
monoglycosylated form). Although the deletion mutants are not subjected to ERAD, the 
impaired trafficking described here shows reduced capacity of the cell to properly deal with 
these proteins. The model proposed earlier for the delay in the endocytosis of truncated PrPs, 
i.e. the binding of PrPc via its N-terminus to a transmembrane receptor promoting 
internalisation of the PrP can also apply to the secretory pathway: The same amino acidic 
stretch could therefore, as a single motif or as part of a larger epitope, together with other 
elements of the molecule, serve as a determinant for inclusion into rafts, proper apical sorting 
and for internalisation from the cell surface. Truncations within this segment decrease the 
affinity for the specific transmembrane receptor and lead therefore to impaired trafficking. 
Since all mutants eventually reach the plasma membrane and can be detected in the endocytic 
pathway, it can be assumed that, as seen with other studies on the trafficking of PrPc, other 
segments of the protein are also involved in the subcellular trafficking or the cells are able to 
switch on alternative pathways for proteins that escape the ER-based quality control. As a 
matter of fact, the plasma membrane domain in which the deletion mutants localise has not 
been characterised, yet. Of note, the phospholipid binding protein annexin XIIIb which binds 
to rafts budding off the TGN and acts at the TGN level and at the cell surface, is apically 
localised and is involved in the formation of apical transport vesicles (Lafont et al., 1998). 
The apical targeting of this protein is determined by a 41 amino acid stretch in its N-terminal 
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tail, as its isoform annexin XIIIa lacks this sequence and is localised basolaterally (Lecat et 
al., 2000). Several proteins interacting with PrPc have been identified using different 
biophysical assays (Kurschner and Morgan, 1996; Edenhofer et al., 1996; Rieger et al., 1997; 
Chebassier et al., 2001), yet the question of whether any of these interactors or a complete 
different molecule is involved in the correct trafficking of PrPc remains open. 
 
4.6  Targeting function of the PrP N-terminus is conserved in evolution 
The involvement of the N-terminus of the mouse PrP in subcellular trafficking led to the 
question of whether the corresponding sequence in the PrPc of more remote species might 
exert the same functions. The recent analysis of Xenopus laevis prion protein (Strumbo et al., 
2001) allowed the construction of a chimeric Xenopus/mouse prion protein and to characterise 
its trafficking. The chimeric and the wild type mouse PrPc shared similar biochemical 
features. Surprisingly, the addition of the Xenopus N-terminal segment to the truncated mouse 
PrP almost restored the wild type trafficking phenotype, and the internalisation and the 
secretory kinetics monitored for this construct significantly differed from those reported for 
PrP∆(23-90) and PrP∆(48-93).  
These data were quite unexpected. In spite of the relatively low identity between the mouse 
and the Xenopus PrPc (28 % for the entire amino acid sequence), the first 34 residues 
following the N-terminal signal peptide in Xenopus mainly retain the character and 
composition of the regions immediately following or preceding the octapeptides in mammals, 
especially in the basic charged N-proximal segment. Still, the Xenopus PrPc lacks the 
octarepeat region and is completely devoid of histidines (Strumbo et al., 2001). The numerous 
lines of evidence collected in vivo and in  vitro  show that transition metals, especially copper, 
bind to PrPc (Brown et al., 1997a). This has suggested several functions for the protein all 
related to the metabolism of these metals. The cooperative binding of copper to the four 
histidines contained within the octapeptide repeats is assumed to be the mechanism 
underlying these functions. The absence of both octapeptides and histidine residues in 
Xenopus suggests that copper binding might not be the primary function of PrPc. Recently, a 
previously unreported high affinity binding site for divalent transition metals around 
histidines 96 and 111 of the human PrPc (Jackson et al., 2001), and additional interaction of 
copper with the structured domain of mouse PrPc was reported (Cereghetti et al., 2001). These 
results seem to confirm the importance of copper in the function of PrPc, and that neuronal 
damage in prion diseases might be a consequence of perturbation in copper transport upon 
conversion of PrPc into PrPSc. Nevertheless, the observation that the histidine content of PrP 
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increases with the evolutionary level (1.5 % and 4 % of the amino acid residues in avian and 
mammalian PrP, respectively), the functional hypothesis concerned with copper binding 
might have developed later in evolution, with the development of the octapeptide repeats as a 
domain of the protein specialised in this role. The reported stimulation of PrPc endocytosis 
upon exposure of neuronal cells to physiologically relevant concentrations of copper or zinc 
contained in the culture medium (Pauly and Harris, 1998; Sumudhu et al., 2001) was not 
assessed in the present study, as no addition of metals was given into the culture medium. 
Nevertheless, relevant levels of copper could already be  present in the culture medium. In the 
case of the chimeric Xenopus/mouse PrPc which was internalised despite the absence of 
histidine residues, the additional binding sites in the C-terminal part of the molecule might 
possibly be sufficient for correct endocytosis. Despite the differences in the polypeptide 
chain, the N-terminal segment of the Xenopus PrPc was able to properly direct subcellular 
trafficking when fused to PrPc of another species. These data argue for a conserved, intrinsic 
sorting function of this segment. 
Although deletion of residues 23-88 of the prion protein did not alter the synthesis of PrPSc in 
cell culture models (Rogers et al., 1993) and mice expressing such a protein were still 
susceptible to prion propagation (Fischer et al., 1996), several works argue for a physiological 
relevance of this segment of the prion protein. Flechsig and collegues showed that mice 
expressing a PrP devoid of residues 23-93 still sustain scrapie infection but with longer 
incubation times. Prion titres and protease resistant PrP are about 30 fold lower than in wild 
type mice, with no histopathology typical for scrapie (Flechsig et al., 2000). These data were 
supported by the in vitro studies performed by Lawson and collegues in which PrPc lacking a 
segment comprising residues 34-94 reduced the conversion efficiency in a cell-free 
conversion assay (Lawson et al., 2001). In light of the results reported here, these findings 
could also be explained by altered intracellular trafficking of the mutated prion protein due to 
the alterations in the N-terminal part. In a different study, the basic N-proximal segment of 
PrPc modifies the binding to the hypothetical protein X by altering the structure of the binding 
epitope therefore influencing the structure of the molecule (Zulianello et al., 2000). Clinical 
studies have shown that addition of two to nine octapeptides to the normal five segregate with 
a familial form of Creutzfeldt Jakob disease (Owen et al., 1989 ; Owen et al., 1990; Owen et 
al., 1992) and non-transmissible prion disease in transgenic mice (Chiesa et al., 2000). 
Analysis of the biochemical properties of such PrP mutants in cell culture revealed 
aggregation and insolubility in non-ionic detergents, and resistance to protease digestion. 
These insertions caused a change in the conformation of the molecule which led to an 
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abnormal association with the plasma membrane when expressed in cultured cells (Shyng et 
al., 1995a). In general, the question remains, whether alterations in the trafficking of PrP and 
of other neurodegenerative proteins are important in the pathogenesis of sporadic forms of 
neurodegenerative disorders. 
 The work described in this study adds to all this evidence and helps delineating a conserved 
biological role of the elusive N-terminus of the prion protein.  Additionally, the finding that 
the trafficking of the chimeric Xenopus/mouse protein was not altered despite the absence of 
octarepeats, argues in favour of a model in which copper binding to the octapeptide repeats 
and subcellular trafficking represent separate aspects in the life-cycle of the prion protein. 
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5 Summary I (English version) 
Transmissible spongiform encephalopathies (TSEs) are degenerative diseases of the central 
nervous system in humans and animals, and include Creutzfeldt-Jakob disease (CJD) in 
humans, scrapie in sheep and bovine spongiform encephalopathy in cattle. These spongiform 
encephalopathies can manifest as sporadic, familial and acquired disorders and are caused by 
the conformational alteration of the non-pathogenic cellular prion protein (PrPc) into a 
infectious isoform denoted PrPSc. The latter therefore represents a pathogenic agent (prion) 
which does not contain nucleic acids. During biogenesis, PrPc undergoes posttranslational 
modifications with the addition of two N-linked carbohydrate chains and a glycosyl-
phosphatidyl-inositol-(GPI)-anchor. Properly folded PrPc transits through the Golgi 
compartment and the secretory pathway and is attached to the outer leaflet of the plasma 
membrane by the GPI-anchor. The cellular function of the prion protein is still unknown, 
although binding of copper to the octapeptide repeat sequence located at its N-terminus 
suggests a role of PrPc related to this phenomenon. 
In the present work, the physiological function of the N-terminal part of PrPc in subcellular 
trafficking was analysed. Metabolic labelling and surface-biotinylation assays were performed 
in order to compare the intracellular trafficking and turnover of PrPc mutants showing specific 
deletions within their N-terminal sequence with those of wild type PrPc (wtPrPc). Upon 
transient expression of these constructs in murine neuroblastoma cells, these deletions, 
although not influencing the biochemical properties or the cell surface expression of these 
proteins, lead to a delay in their endocytosis. The prolongation of the internalisation kinetics 
was shown to be dependent on the length of the deletion: truncation of the complete N-
terminus leads to the almost complete inhibition of internalisation. The analysis of the kinetics 
of degradation showed a similar correlation with the N-terminal part of PrPc, since the half-
life of the PrP-mutants was significantly prolonged when compared to that of the wild type 
protein. Additionally performed detailed analysis of the secretory pathway with 
immunoprecipitation assays showed that N-terminally truncated PrP molecules reach the 
plasma membrane at a later time point, when compared with wtPrPc. A closer analysis of the 
processing of the sugar molecules linked to these proteins performing an Endo-H digestion 
revealed that this delay in the transport to the cell surface takes place in a cellular 
compartment following the mid-Golgi. 
The following studies were done with a chimeric protein consisting of the short N-terminal 
segment of Xenopus laevis, which does not contain the copper-binding octarepeat region, 
fused to the N-terminally truncated mouse PrPc. These studies showed that endocytosis of this 
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protein and its transport through the secretory pathway were comparable to those of the 
mouse wtPrPc. It was therefore concluded that the N-terminus belonging to a phylogenetically 
remote species can rescue the wild type trafficking phenotype. 
These results indicate that the N-proximal domain of the prion protein functions as a targeting 
element and is essential for both transport to the plasma membrane and modulation of 
endocytosis. The data support a model in which the N-terminal part of PrPc represents an 
epitope for binding to a transmembrane receptor containing internalisation-promoting motifs 
or for inclusion of PrPc into the secretory raft-compartments. The present work also indicates 
for the first time that copper affinity of the octarepeats and subcellular trafficking represent 
separate aspects in the life-cycle of the prion protein.  
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6 Summary II (German version) 
Die transmissiblen spongiformen Enzephalopathien (TSEs) bilden eine Gruppe fataler 
degenerativer Erkrankungen des zentralen Nervensystems von Mensch und Tier, deren 
bekannteste Erscheinungsformen die bovine spongiforme Enzephalopathie (BSE) beim Rind, 
die Traberkrankheit beim Schaf sowie die Creutzfeldt-Jakob-Erkrankung beim Menschen 
sind. Diese Erkrankungen können als Folge von Mutationen familiär-genetisch bedingt sein, 
infektiös erworben werden oder ohne erkennbare Ursache (sporadisch) auftreten. Das 
Auftreten und die Übertragung dieser Erkrankungen sind auf eine posttranslationale 
Umwandlung des apathogenen zellulären Prion-Proteins (PrPc) in eine infektiöse Isoform 
(Scrapie-Form, PrPSc) zurückzuführen, sodass dieses Protein ohne eine damit assoziierte 
Nukleinsäure als pathogenes Agens (Prion) fungiert. PrPc wird posttranslational glykosyliert 
und gelangt im Verlauf seiner Maturierung entlang des sekretorischen Transportwegs an die 
Zelloberfläche, an die es durch einen GPI-Anker verknüpft wird. Die Funktion des Prion-
Proteins ist noch unbekannt, obwohl mehrere Untersuchungen eine Bindung von Kupfer an 
die N-terminal vorliegenden  „Octarepeats“ von PrPc feststellen konnten und deshalb dem 
Prion-Protein eine mit dieser Eigenschaft in Zusammenhang stehende Funktion zugeschrieben 
wird. 
In der vorliegenden Arbeit wurde die physiologische Funktion des N-terminalen Anteils von 
PrPc im intrazellulären Transport untersucht. Mittels metabolischer Markierung und 
Oberflächen-Biotinylierung wurde das Verhalten und die Halbwertszeit von PrP-Mutanten, 
die spezifische Deletionen in der N-terminalen Sequenz aufweisen, mit denen des Wildtyp-
Proteins (wtPrPc) verglichen. Nach transienter Expression dieser Mutanten in murinen 
Neuroblastomzellen konnte gezeigt werden, dass die Deletionen weder die biochemischen 
Eigenschaften noch die Zelloberfächenexpression dieser Proteine beeinflussen, aber dennoch 
zu einer signifikanten Verlangsamung ihrer Endozytose führen. Die Verlängerung der 
Internalisierungskinetik erwies sich als abhängig von der Länge der Deletion: die Abspaltung 
des kompletten N-Terminus erbrachte nahezu eine Inhibierung der Internalisierung des 
Proteins. Eine Analyse der Degradationskinetik zeigte weiterhin, dass dieser Prozess im 
gleichen Zusammenhang mit dem N-terminalen Bereich von PrPc steht, da die Halbwertszeit 
der untersuchten PrP-Mutanten deutlich länger ist als die des Wildtyp-Proteins. Wie durch 
detaillierte Analyse des sekretorischen Transportweges mittels Immunpräzipitation weiterhin 
gezeigt werden konnte, erreichen N-terminal verkürzte PrPs die äußere Plasmamembran zu 
einem späteren Zeitpunkt als das wtPrPc. Die Untersuchung der Glykosylierung dieser 
Proteine mittels Endo-H Verdau ergab, dass die Verzögerungen im Transport zur 
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Zelloberfläche erst stattfinden, nachdem PrPc das mid-Golgi Kompartiment erreicht hat. Die 
Analyse eines chimären PrPs, bestehend aus dem N-Terminus von Xenopus laevis, der keine 
für die Kupferbindung wichtigen Octapeptide enthält, und aus einem N-terminal verkürztem 
Maus PrP, zeigte, dass sowohl die Endozytose als auch der sekretorische Transportweg dieses 
Proteins mit dem von murinem wtPrPc vergleichbar waren. Daraus konnte man schließen, 
dass der N-Terminus einer phylogenetisch entfernten Spezies den Wildtyp-Phenotyp 
wiederherstellen kann. 
Diese Ergebnisse deuten auf eine wichtige, konservierte Funktion des N-Terminus von PrPc 
im gesamten intrazellulären Transport, indem er als Signal für die korrekte Internalisierung 
und für die Beförderung an die Zelloberfläche dient. Die vorliegenden Daten unterstützen ein 
Modell, in dem der N-terminale Anteil des Prion-Proteins eine Bindungsstelle für einen 
transmembranen Rezeptor darstellt, der die Internalisierung bzw. die Eingliederung von PrPc 
in die sekretorischen Raft-Kompartimente begünstigt. Es konnte weiterhin erstmals gezeigt 
werden, dass Kupferbindung an die Octapeptide und intrazellulärer Transport voneinander 
unabhängige Entitäten im Lebenszyklus des Prion-Proteins darstellen. 
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8 Abbreviations  
 
APS  ammoniumpersulfate 
ATCC  American Type Culture Collection 
Aa  amino acid 
BHK  baby hamster kidney (cells) 
Bp  base pairs  
BSE   bovine spongiform encephalopathy  
CHO  Chinese hamster ovary (cells) 
Ci  Curie 
CD  circular dichroism  
CJD  Creutzfeldt-Jakob disease 
CLD  caveolae-like domains 
CNS  central nervous system 
CWD  chronic wasting disease  
Cys  cysteine 
DMEM Dulbecco´s modified Eagle medium 
DNA  deoxyribonucleic acid 
dNTP   deoxynucleotide 
ER  endoplasmic reticulum  
ERAD  ER-associated degradation  
ERGIC ER-Golgi intermediate compartment  
EDTA  ethylenediaminetetraacetate 
Endo-H Endoglycosidase-H  
EtOH  ethanol 
FCS  fetal calf serum 
FDC  follicular dendritic cells 
FFI  fatal familial insomnia  
FITC  Fluorescein - Isothyocianate 
FSE  feline spongiform encephalopathy 
FTIR  Fourier-transform infrared spectroscopy  
GPI  glycosyl-phosphatidyl-inositol 
GSS  Gerstmann-Sträußler-Scheinker disease 
KDa  kilodalton 
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LR  laminin receptor 
LRP  laminin receptor precursor 
mAb   monoclonal antibody 
MEM  minimal essential medium 
Meth  methionine 
MetOH methanol 
NMR  nuclear magnetic resonance 
OD  optical density 
ORF  open reading frame 
pAB   ployclonal antibody 
PAGE  polyacrylamide gel electrophoresis  
PCR  polymerase chain reaction 
PNGase F N-Glycosidase F 
PrP  prion protein 
PrPc  cellular non-pathogenic form of the prion protein 
PrPSc  pathogenic form of the prion protein 
PK  Proteinase K 
REC  recycling endocytic compartment  
RT  room temperature 
SDS   sodium dodecyl sulfate  
SE  sorting endosome  
TEMED N,N,N,N-tetramethylethylendiamin 
TGN  trans-Golgi network 
TME  transmissible mink encephalopathy  
TSE  transmissible spongiform encephalopathy 
wt  wild type       
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